<SEC-DOCUMENT>0001193125-23-054410.txt : 20230301
<SEC-HEADER>0001193125-23-054410.hdr.sgml : 20230301
<ACCEPTANCE-DATETIME>20230228181218
ACCESSION NUMBER:		0001193125-23-054410
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230227
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230301
DATE AS OF CHANGE:		20230228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HUMANA INC
		CENTRAL INDEX KEY:			0000049071
		STANDARD INDUSTRIAL CLASSIFICATION:	HOSPITAL & MEDICAL SERVICE PLANS [6324]
		IRS NUMBER:				610647538
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-05975
		FILM NUMBER:		23688216

	BUSINESS ADDRESS:	
		STREET 1:		500 W MAIN ST
		CITY:			LOUISVILLE
		STATE:			KY
		ZIP:			40202
		BUSINESS PHONE:		5025801000

	MAIL ADDRESS:	
		STREET 1:		500 W. MAIN ST
		CITY:			LOUISVILLE
		STATE:			KY
		ZIP:			40202

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXTENDICARE INC
		DATE OF NAME CHANGE:	19740404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HERITAGE HOUSE OF AMERICA INC
		DATE OF NAME CHANGE:	19671129
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d461254d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:hum="http://www.humana.com/20230227" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2023-02-27_to_2023-02-27">HUMANA INC</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-02-27_to_2023-02-27">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-02-27_to_2023-02-27">0000049071</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="hum-20230227.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-02-27_to_2023-02-27"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-02-27</xbrli:startDate> <xbrli:endDate>2023-02-27</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, DC 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-02-27_to_2023-02-27">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): February 28, 2023 (<ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-02-27_to_2023-02-27" format="ixt:datemonthdayyearen">February 27, 2023</ix:nonNumeric>)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">Humana Inc.</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-02-27_to_2023-02-27" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-02-27_to_2023-02-27">001-05975</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-02-27_to_2023-02-27">61-0647538</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-02-27_to_2023-02-27">500 W. Main Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-02-27_to_2023-02-27">Louisville</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-02-27_to_2023-02-27" format="ixt-sec:stateprovnameen">Kentucky</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-02-27_to_2023-02-27">40202</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, and Zip Code)</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-02-27_to_2023-02-27">(502)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-02-27_to_2023-02-27">580-1000</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<span style="font-style:italic">see</span> General Instruction A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-02-27_to_2023-02-27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-02-27_to_2023-02-27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-02-27_to_2023-02-27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-02-27_to_2023-02-27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-02-27_to_2023-02-27">Common Stock</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-02-27_to_2023-02-27">HUM</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-02-27_to_2023-02-27" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-02-27_to_2023-02-27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On February&#160;27, 2023, Humana Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Barclays Capital Inc., Citigroup Global Markets Inc., Morgan Stanley&#160;&amp; Co. LLC, U.S. Bancorp Investments, Inc. and Wells Fargo Securities, LLC, as representatives of the several underwriters (together, the &#8220;Underwriters&#8221;), pursuant to which the Company agreed to issue and sell to the Underwriters $500&#160;million aggregate principal amount of its 5.700% Senior Notes due 2026 (the &#8220;2026 Senior Notes&#8221;) and $750&#160;million aggregate principal amount of its 5.500% Senior Notes due 2053 (the &#8220;2053 Senior Notes&#8221; and, together with the 2026 Senior Notes, the &#8220;Senior Notes&#8221;), in accordance with the terms and conditions set forth in the Underwriting Agreement. The 2026 Senior Notes were sold at a public offering price of 99.984% of the aggregate principal amount thereof and the 2053 Senior Notes were sold at a public offering price of 96.431% of the aggregate principal amount thereof. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sale of the Senior Notes has been registered with the Securities and Exchange Commission (the &#8220;Commission&#8221;) in a registration statement on Form <span style="white-space:nowrap">S-3,</span> File <span style="white-space:nowrap">No.&#160;333-254041</span> (the &#8220;Registration Statement&#8221;). The terms of the Senior Notes are described in the Company&#8217;s Prospectus dated March&#160;9, 2021, as supplemented by a final Prospectus Supplement dated February&#160;27, 2023 as filed with the Commission on February&#160;28, 2023, pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Senior Notes are unsecured senior obligations of the Company and rank equally with all of the Company&#8217;s other unsecured, unsubordinated indebtedness. The 2026 Senior Notes bear interest at an annual rate of 5.700% and the 2053 Senior Notes bear interest at an annual rate of 5.500%. Interest on the 2026 Senior Notes is payable by the Company on March&#160;13 and September&#160;13 of each year, beginning on September&#160;13, 2023. Interest on the 2053 Senior Notes is payable by the Company on March&#160;15 and September&#160;15 of each year, beginning on September&#160;15, 2023. The 2026 Senior Notes mature on March&#160;13, 2026 and the 2053 Senior Notes mature on March&#160;15, 2053. The closing of the sale of the Senior Notes is expected to occur on March&#160;13, 2023, subject to customary closing conditions. The Company estimates that the net proceeds from the sale of the Senior Notes, after deducting the Underwriters&#8217; discounts and commissions and estimated offering expenses, will be approximately $1.211&#160;billion. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Underwriters and their affiliates have performed commercial banking, investment banking and advisory services for the Company from time to time for which they have received customary fees and expenses. The Underwriters and their affiliates may, from time to time, engage in transactions with and perform services for the Company in the ordinary course of their business. In addition, certain affiliates of the Underwriters are lenders under the Company&#8217;s revolving credit facility, <span style="white-space:nowrap">364-day</span> credit facility and term loan, and the Underwriters or their affiliates may hold the Company&#8217;s existing senior notes for their own accounts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company intends to use the net proceeds from the Senior Notes offering to repay outstanding amounts under its $500&#160;million Delayed Draw Term Loan. Net proceeds from the Senior Notes offering in excess of the amount required to repay outstanding borrowings under its Delayed Draw Term Loan at the time the Senior Notes offering is completed will be used for general corporate purposes, which may include the repayment of borrowings under its commercial paper program. As of December&#160;31, 2022, the outstanding balance under the Company&#8217;s Delayed Draw Term Loan was $500&#160;million and the interest rate in effect on that outstanding balance was LIBOR plus 125 basis points. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of the Underwriting Agreement is filed as Exhibit 1.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated by reference herein. The description of the material terms of the Underwriting Agreement is qualified in its entirety by reference to such exhibit. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item.&#160;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company issued a press release announcing the pricing of the offering of the Senior Notes, which is attached as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is hereby incorporated by reference herein. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d461254dex11.htm">Underwriting Agreement, dated February&#160;27, 2023, among the Company, Barclays Capital Inc., Citigroup Global Markets Inc., Morgan Stanley&#160;&amp; Co. LLC, U.S. Bancorp Investments, Inc. and Wells Fargo Securities, LLC, as representatives of the several underwriters. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d461254dex991.htm">Press Release, dated February&#160;27, 2023 issued by the Company. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:8%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:91%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">HUMANA INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">BY:</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;font-weight:bold">/s/ John-Paul W. Felter</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">John-Paul W. Felter</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Senior Vice President, Chief Accounting Officer and Controller</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(Principal Accounting Officer)</p></td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: February&#160;28, 2023 </p>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d461254dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>$1,250,000,000 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HUMANA
INC. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>$500,000,000 5.700% Senior Notes due 2026 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>$750,000,000 5.500% Senior Notes due 2053 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>UNDERWRITING AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">February&nbsp;27, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B<SMALL>ARCLAYS</SMALL>
C<SMALL>APITAL</SMALL> I<SMALL>NC</SMALL>. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">C<SMALL>ITIGROUP</SMALL> G<SMALL>LOBAL</SMALL> M<SMALL>ARKETS</SMALL> I<SMALL>NC</SMALL>. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">M<SMALL>ORGAN</SMALL> S<SMALL>TANLEY</SMALL>&nbsp;&amp; C<SMALL>O</SMALL>. LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. B<SMALL>ANCORP</SMALL> I<SMALL>NVESTMENTS</SMALL>, I<SMALL>NC</SMALL>. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">W<SMALL>ELLS</SMALL> F<SMALL>ARGO</SMALL> S<SMALL>ECURITIES</SMALL>, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the several </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Underwriters named in Schedule
1 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Barclays Capital Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">745 Seventh Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10019 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Citigroup Global Markets Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">388 Greenwich Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10013 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Morgan Stanley&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1585 Broadway </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10036 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o U.S. Bancorp Investments, Inc.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">214 North Tryon Street, 26th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charlotte, North
Carolina 28202 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Wells Fargo Securities, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">550 South
Tryon Street, 5th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charlotte, North Carolina 28202 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Humana Inc., a Delaware corporation (the &#147;Company&#148;), proposes to sell (i) $500,000,000 in aggregate principal amount of the Company&#146;s 5.700%
Senior Notes due 2026 (the &#147;2026 Notes&#148;) and (ii) $750,000,000 in aggregate principal amount of the Company&#146;s 5.500% Senior Notes due 2053 (the &#147;2053 Notes&#148; and, together with the 2026 Notes, the &#147;Notes&#148;). The 2026
Notes are to be issued pursuant to an Indenture, dated as of August&nbsp;5, 2003 (the &#147;Base Indenture&#148;), as supplemented by the Twenty-Fourth Supplemental Indenture, to be dated as of March&nbsp;13, 2023 (the &#147;2026 Notes Supplemental
Indenture&#148;; the Base Indenture, as supplemented by the 2026 Notes Supplemental Indenture, the &#147;2026 Notes Indenture&#148;), to be entered into between the Company and The Bank of New York Mellon Trust Company, N.A. (formerly known as The
Bank of New York Trust Company, N.A.) (as successor to The Bank of New York)<I>,</I> as trustee (the &#147;Trustee&#148;). The 2053 Notes are to be issued pursuant to the Base Indenture, as supplemented by the Twenty-Fifth Supplemental Indenture, to
be dated as of March&nbsp;13, 2023 (the &#147;2053 Notes Supplemental Indenture&#148;; the Base Indenture, as supplemented by the 2053 Notes Supplemental Indenture, the &#147;2053 Notes Indenture&#148; and, together with the 2026 Notes Indenture,
the &#147;Indentures&#148;), to be entered into between the Company and the Trustee. This is to confirm the agreement concerning the purchase of the Notes from the Company by the Underwriters named in Schedule 1 hereto (the
&#147;Underwriters&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <I>Representations, Warranties and Agreements of the Company</I>. The Company represents, warrants and
agrees that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) A registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> with respect to the Notes
has (i)&nbsp;been prepared by the Company in conformity with the requirements of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), and the rules and regulations (the &#147;Rules and Regulations&#148;) of the Securities and
Exchange Commission (the &#147;Commission&#148;) thereunder, (ii)&nbsp;been filed with the Commission under the Securities Act and (iii)&nbsp;become effective under the Securities Act; and the Base Indenture has been qualified under the Trust
Indenture Act of 1939, as amended (the &#147;Trust Indenture Act&#148;). Copies of such registration statement and any amendments thereto have been delivered by the Company to you as the Representatives (the &#147;Representatives&#148;) of the
Underwriters. The Company has also filed, or proposes to file, with the Commission pursuant to Rule 424 under the Securities Act a prospectus supplement specifically relating to the Notes (the &#147;Prospectus Supplement&#148;). As used in this
Agreement, &#147;Effective Time&#148; means the date and the time as of which any part of such registration statement became, or is deemed to have become, effective under the Securities Act in accordance with the Rules and Regulations;
&#147;Effective Date&#148; means the date of any Effective Time; &#147;Issuer Free Writing Prospectus&#148; means each &#147;free writing prospectus&#148; (as defined in Rule 405 of the Rules and Regulations) prepared by or on behalf of the Company
or used or referred to by the Company in connection with the offering of the Notes; &#147;Preliminary Prospectus&#148; means each preliminary prospectus included in such registration statement, or amendments thereof, or filed with the Commission by
the Company with the consent of the Representatives, as provided herein, pursuant to Rule 424(b) of the Rules and Regulations and the preliminary prospectus supplement specifically relating to the Notes; &#147;Registration Statement&#148; means such
registration statement, as amended at the most recent Effective Time, including any documents incorporated by reference therein at such time and all information contained in the final Prospectus filed with the Commission pursuant to Rule 424(b) of
the Rules and Regulations in accordance with Section&nbsp;5(a) hereof and deemed to be a part of the registration statement as of such Effective Time pursuant to Rule 430A, Rule 430B or Rule </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
430C of the Rules and Regulations; &#147;Prospectus&#148; means such final prospectus as supplemented by the Prospectus Supplement specifically relating to the Notes in the form first used to
confirm sales of the Notes and as filed with the Commission pursuant to Rule 424(b) of the Rules and Regulations; &#147;Time of Sale&#148; means the time when sales or contracts for sales of the Notes were first made; and &#147;Pricing Disclosure
Package&#148; means, as of the Time of Sale, the most recent Preliminary Prospectus, together with each Issuer Free Writing Prospectus listed on Schedule 2(A) hereto. Reference made herein to any Preliminary Prospectus or to the Prospectus shall be
deemed to refer to and include any documents incorporated by reference therein pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, as of the date of such Preliminary Prospectus or the Prospectus, as the
case may be, and any reference to any amendment or supplement to any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any document filed under the Securities Exchange Act of 1934, as amended (the &#147;Exchange
Act&#148;), after the date of such Preliminary Prospectus or the Prospectus, as the case may be, and incorporated by reference in such Preliminary Prospectus or the Prospectus, as the case may be; and any reference to any amendment to the
Registration Statement shall be deemed to include any annual report of the Company filed with the Commission pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act after the initial Effective Time that is incorporated by reference in the
Registration Statement. The Commission has not issued any order preventing or suspending the use of any Preliminary Prospectus or the Prospectus or suspending the effectiveness of the Registration Statement, and no proceeding or examination for such
purpose has, to the knowledge of the Company, been instituted or threatened by the Commission. The Commission has not notified the Company of any objection to the use of the form of the Registration Statement pursuant to Rule 401(g)(2) of the Rules
and Regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company has at all times since the time of the initial filing of the Registration Statement been
and continues to be a &#147;well-known seasoned issuer&#148; (as defined in Rule 405 of the Rules and Regulations) eligible to use Form <FONT STYLE="white-space:nowrap">S-3</FONT> for the offering of the Notes, including not having been an
&#147;ineligible issuer&#148; (as defined in Rule 405 of the Rules and Regulations) at any time since such time, and is not the subject of a pending proceeding under Section&nbsp;8A of the Securities Act. The Registration Statement is an
&#147;automatic shelf registration statement&#148; (as defined in Rule 405 of the Rules and Regulations) and was filed not earlier than the date that is three years prior to the Delivery Date (as defined in Section&nbsp;4). The conditions for use of
Form <FONT STYLE="white-space:nowrap">S-3,</FONT> as set forth in the General Instructions thereto, have been satisfied. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Registration Statement conformed and will conform in all material respects on each applicable Effective Date and on the
Delivery Date, and any amendment to the Registration Statement filed after the date hereof will conform in all material respects when filed, to the requirements of the Securities Act and the Rules and Regulations. The Preliminary Prospectus
conformed, and the Prospectus will conform, in all material respects when filed with the Commission pursuant to Rule 424(b) and on the Delivery Date to the requirements of the Securities Act and the Rules and Regulations. The documents incorporated
by reference into the Pricing Disclosure Package or the Prospectus conformed, and any further documents so incorporated will conform, when filed with the Commission, in all material respects to the requirements of the Exchange Act or the Securities
Act, as applicable, and the rules and regulations of the Commission thereunder. The Base Indenture conforms, and each Indenture will conform, in all material respects to the requirements of the Trust Indenture Act and the applicable rules and
regulations thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Registration Statement did not, as of each applicable Effective
Date, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; provided that no representation or warranty is made as to information
contained in or omitted from the Registration Statement in reliance upon and in conformity with the Underwriters&#146; Information (as defined in Section&nbsp;8(e)). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Prospectus will not, as of its date, the date of any amendment or supplement thereto or the Delivery Date, contain an
untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading; provided that no representation
or warranty is made as to information contained in or omitted from the Prospectus in reliance upon and in conformity with the Underwriters&#146; Information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) The documents incorporated by reference in the Registration Statement, the Pricing Disclosure Package or the Prospectus did
not, and any further documents filed and incorporated by reference therein will not, when filed with the Commission, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make
the statements therein, in light of the circumstances under which they were made, not misleading. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) The Pricing
Disclosure Package as of the Time of Sale did not, and at the Delivery Date will not, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light
of the circumstances under which they were made, not misleading; provided that no representation or warranty is made as to information contained in or omitted from the Pricing Disclosure Package in reliance upon and in conformity with the
Underwriters&#146; Information. No statement of material fact included in the Prospectus has been omitted from the Pricing Disclosure Package, and no statement of material fact included in the Pricing Disclosure Package that is required to be
included in the Prospectus has been omitted therefrom. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) Each Issuer Free Writing Prospectus conformed or will conform
in all material respects to the requirements of the Securities Act and the Rules and Regulations on the date of first use, and the Company has complied with any filing requirements applicable to such Issuer Free Writing Prospectus pursuant to the
Rules and Regulations. No Issuer Free Writing Prospectus includes any information that conflicts with the information contained in the Registration Statement, including any document incorporated therein and any prospectus supplement deemed to be a
part thereof that has not been superseded or modified. The Company has retained in accordance with the Rules and Regulations all Issuer Free Writing Prospectuses that were not required to be filed pursuant to the Rules and Regulations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company has not distributed and, prior to the completion of the
delivery of the Notes, will not distribute, any offering material in connection with the offering and sale of the Notes other than any Preliminary Prospectus, the Prospectus and any Issuer Free Writing Prospectus set forth on Schedule 2 hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) (i) The Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the
State of Delaware, (ii)&nbsp;each of the Company&#146;s subsidiaries (as defined in Section&nbsp;16) has been duly organized and is validly existing and in good standing under the laws of its respective jurisdiction of organization, and
(iii)&nbsp;except as would not result in a material adverse effect on the business, properties, results of operations or financial condition of the Company and its subsidiaries, taken as a whole (a &#147;Material Adverse Effect&#148;), the Company
and each of its subsidiaries are duly qualified to do business and are in good standing in each jurisdiction in which their respective ownership or lease of property or the conduct of their respective businesses requires such qualification. The
Company and each of its subsidiaries have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are engaged, and none of the subsidiaries of the Company is a &#147;significant
subsidiary&#148; (as such term is defined in Rule 405 of the Rules and Regulations) except for Humana Insurance Company, Humana Medical Plan, Inc., CenterWell Pharmacy, Inc. and CenterWell Health Services, Inc.<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP>(together, the &#147;Significant Subsidiaries&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) The Company has
an authorized capitalization as set forth in the Preliminary Prospectus and the Prospectus in the column entitled &#147;Actual&#148; under the caption &#147;Capitalization&#148;, and all of the issued shares of capital stock of the Company have been
duly and validly authorized and issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and conform in all material respects to the description thereof contained in the Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2022; and all of the issued shares of capital stock or other equity interest of each subsidiary of the Company have been duly and validly authorized and issued
and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and (except for directors&#146; qualifying shares or as set forth on Schedule 3 hereto) are owned directly or indirectly by the Company, free and clear of all liens,
encumbrances, equities or claims. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) The Company has all requisite power and authority to execute, deliver and perform
its obligations under the Base Indenture, the 2026 Notes Supplemental Indenture, the 2053 Notes Supplemental Indenture and the Notes; and the Base Indenture has been duly authorized, executed and delivered by the Company, and constitutes a valid and
binding agreement of the Company enforceable against the Company in accordance with its terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws relating to or affecting
creditors&#146; rights generally, general equitable principles (whether considered in a proceeding in equity or at law) or an implied covenant of good faith and fair dealing; and each of the 2026 Notes Supplemental Indenture and the 2053 Notes
Supplemental Indenture has been duly authorized, and when duly executed by the proper officers of the Company (assuming due execution and delivery by the Trustee) and delivered by the Company, each Indenture will
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
constitute a valid and binding agreement of the Company enforceable against the Company in accordance with its terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance,
reorganization, moratorium and other similar laws relating to or affecting creditors&#146; rights generally, general equitable principles (whether considered in a proceeding in equity or at law) or an implied covenant of good faith and fair dealing;
and the Notes have been duly authorized, and, when duly executed, authenticated, issued and delivered as provided in the applicable Indenture, will be duly and validly issued and outstanding, and will constitute valid and binding obligations of the
Company entitled to the benefits of such Indenture and enforceable in accordance with their terms, subject to the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar laws relating to or affecting
creditors&#146; rights generally, general equitable principles (whether considered in a proceeding in equity or at law) or an implied covenant of good faith and fair dealing; and each of the 2026 Notes Indenture and the 2053 Notes Indenture, when
executed and delivered, and the Notes, when issued and delivered, will conform to the descriptions thereof contained in the Pricing Disclosure Package and the Prospectus in all material respects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) The Company has all requisite corporate power and authority to enter into this Agreement; and this Agreement has been duly
authorized, executed and delivered by the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) The execution, delivery and performance of this Agreement and each
Indenture by the Company and the consummation of the transactions contemplated hereby and thereby, and the issuance and delivery of the Notes will not conflict with or result in a breach or violation of any of the terms or provisions of, or
constitute a default under, any indenture, mortgage, deed of trust, loan agreement, agreement with any governmental or regulatory authority to which the Company or any of its Significant Subsidiaries is a party or by which the Company or any of its
Significant Subsidiaries is bound or to which any of the property or assets of the Company or its Significant Subsidiaries is subject, or any other material agreement or instrument to which the Company or any of its subsidiaries is a party or by
which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject, nor will such actions result in any violation of the provisions of (i)&nbsp;the charter or <FONT
STYLE="white-space:nowrap">by-laws</FONT> (or other similar organizational documents) of the Company or any of its subsidiaries or (ii)&nbsp;any statute or any order, rule or regulation of any governmental agency or body or court having jurisdiction
over the Company or any of its subsidiaries or any of their properties or assets, except, in the case of clause (ii), such violations as would not have a Material Adverse Effect; and except for the registration of the Notes under the Securities Act
and such consents, approvals, authorizations, registrations or qualifications as may be required under the Trust Indenture Act and applicable foreign or state securities or blue sky laws in connection with the purchase and distribution of the Notes
by the Underwriters, no consent, approval, authorization or order of, or filing or registration with, any such governmental agency or body or court is required for the execution, delivery and performance of this Agreement or the Indentures by the
Company and the consummation of the transactions contemplated hereby and thereby and the issuance and sale of the Notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) There are no contracts, agreements or understandings between the Company
and any person granting such person the right to require the Company to include any securities other than the Notes in the securities registered pursuant to the Registration Statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) Neither the Company nor any of its subsidiaries has sustained, since the date of the latest audited financial statements
included or incorporated by reference in the Preliminary Prospectus and the Prospectus, any material loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute
or court or governmental action, order or decree, otherwise than as set forth in the Pricing Disclosure Package and the Prospectus; and, since such date, there has not been any change in the capital stock or
<FONT STYLE="white-space:nowrap">long-term</FONT> debt of the Company or any of its subsidiaries or any Material Adverse Effect, otherwise than as set forth in the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) The financial statements (including the related notes and any supporting schedules) filed as part of the Registration
Statement or included or incorporated by reference in the Pricing Disclosure Package and the Prospectus present fairly the financial condition and results of operations of the entities purported to be shown thereby, at the dates and for the periods
indicated, and have been prepared in conformity with generally accepted accounting principles in the United States applied on a consistent basis throughout the periods involved. The interactive data in eXtensible Business Reporting Language included
or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the Commission&#146;s rules and
guidelines applicable thereto. No pro forma financial information is required to be filed with the Commission pursuant to Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> with respect to any acquisitions or dispositions by the Company since
January&nbsp;1, 2022. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) PricewaterhouseCoopers LLP, who have certified certain financial statements of the Company,
whose report is incorporated by reference in the Registration Statement, the Preliminary Prospectus and the Prospectus and who have delivered the initial letter referred to in Section&nbsp;7(g) hereof, is an independent registered public accounting
firm with respect to the Company within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the Securities Act and the Rules and Regulations during the
periods covered by the financial statements on which it reported and which are contained or incorporated in the Registration Statement, the Preliminary Prospectus and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) The Company and each of its subsidiaries have good and marketable title in fee simple to all real property and good and
valid title to all personal property owned by them, in each case free and clear of all liens, encumbrances and defects except such as are described in the Pricing Disclosure Package and the Prospectus or such as do not materially affect the value of
such property and do not materially interfere with the use made and proposed to be made of such property by the Company and its subsidiaries; and all real property and buildings held under lease by the Company and its subsidiaries are held by them
under valid, subsisting and enforceable leases, with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company and its subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) The Company and each of its subsidiaries carry, or are covered by,
insurance in such amounts and covering such risks as is adequate for the conduct of their respective businesses and the value of their respective properties and as is customary for companies engaged in similar businesses in similar industries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) The Company and each of its subsidiaries own or possess adequate rights to use all material patents, patent applications,
trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights and licenses necessary for the conduct of their respective businesses and have no reason to believe that the conduct of their respective
businesses will conflict with, and have not received any notice of any claim of conflict with, any such rights of others, except for such claims as would not have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Other than as expressly set forth in the Pricing Disclosure Package and the Prospectus, there are no legal or governmental
proceedings pending to which the Company or any of its subsidiaries is a party or of which any property or assets of the Company or any of its subsidiaries is the subject which, if determined adversely to the Company or any of its subsidiaries,
could reasonably be expected to have a Material Adverse Effect; and to the Company&#146;s knowledge, no such proceedings are threatened or contemplated by governmental authorities or threatened by others. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) There are no contracts or other documents which are required to be described in the Preliminary Prospectus and the
Prospectus or filed as exhibits to the Registration Statement by the Securities Act or by the Rules and Regulations which have not been described in the Preliminary Prospectus and the Prospectus or filed as exhibits to the Registration Statement or
incorporated therein by reference as permitted by the Rules and Regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) No relationship, direct or indirect,
exists between or among the Company or any of its subsidiaries, on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company or any of its subsidiaries, on the other hand, that is required to be described or
incorporated by reference in the Preliminary Prospectus and the Prospectus which is not so described or incorporated by reference. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) No labor disturbance by the employees of the Company exists or, to the knowledge of the Company, is imminent which might be
expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) The Company and each of its subsidiaries are in compliance with all
applicable federal and state statutes, regulations, rules and orders relating to the healthcare and insurance industries, in each case with such exceptions as would not have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) There has been no, and the Company and its subsidiaries have not been
notified of and have no knowledge of any, event or condition that would reasonably be expected to result in an information security breach or other compromise of any of the Company&#146;s or any of its subsidiaries&#146; information technology and
computer systems, networks, hardware, software, data, equipment or technology (including the foregoing of their respective customers, employees, suppliers and vendors with respect to the Company and its subsidiaries&#146; businesses) (collectively,
&#147;IT Systems and Data&#148;), where such security breach or compromise has had or would have, individually or in the aggregate, a Material Adverse Effect. The Company and its subsidiaries (i)&nbsp;are presently in compliance with all applicable
laws or statutes and all judgments, orders, rules and regulations of any court, arbitrator or governmental or regulatory authority, internal policies and contractual obligations, in each case, relating to the privacy and security of IT Systems and
Data, and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except for any <FONT STYLE="white-space:nowrap">non-compliance</FONT> that would not, individually or in the aggregate, have a
Material Adverse Effect; and (ii)&nbsp;have implemented backup and disaster recovery technology consistent with industry standards and practices. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) The Company is in compliance in all material respects with all applicable provisions of the Employee Retirement Income
Security Act of 1974, as amended, including the regulations and published interpretations thereunder (&#147;ERISA&#148;); to the best of the Company&#146;s knowledge no &#147;reportable event&#148; (as defined in ERISA) has occurred with respect to
any &#147;pension plan&#148; (as defined in ERISA) for which the Company would have any material liability; to the best of the Company&#146;s knowledge the Company has not incurred and does not expect to incur any material liability under
(i)&nbsp;Title IV of ERISA with respect to termination of, or withdrawal from, any &#147;pension plan&#148; or (ii)&nbsp;Sections 412 or 4971 of the Internal Revenue Code of 1986, as amended, including the regulations and published interpretations
thereunder (the &#147;Code&#148;); and each &#147;pension plan&#148; for which the Company would have any liability that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified in all material respects and to the best of
the Company&#146;s knowledge nothing has occurred, whether by action or by failure to act, which would cause the loss of such qualification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) Except as would not have a Material Adverse Effect, the Company has filed all federal, state, local and foreign tax
returns required to be filed through the date hereof and has paid all taxes due thereon. No tax deficiency has been determined adversely to the Company or any of its subsidiaries which has had (nor does the Company have any knowledge of any tax
deficiency which, if determined adversely to the Company or any of its subsidiaries, might have) a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) Since the date as of which information is given in the Pricing Disclosure Package through the date hereof, and except as
may otherwise be disclosed in the Pricing Disclosure Package, the Company has not (i)&nbsp;issued or granted any securities except for employee stock options and restricted stock awards, (ii)&nbsp;incurred any liability or obligation, direct or
contingent, other than liabilities and obligations which were incurred in the ordinary course of business, (iii)&nbsp;entered into any transaction not in the ordinary course of business or (iv)&nbsp;declared or paid any dividend on its capital
stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) None of the Company or any of its subsidiaries (i)&nbsp;is in violation
of its charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> (or other similar organizational documents), (ii) is in default in any respect, and to the best of the Company&#146;s knowledge, no event has occurred which, with notice or lapse of
time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which it is a party or by
which it is bound or to which any of its properties or assets is subject or (iii)&nbsp;is in violation in any respect of any law, ordinance, governmental rule, regulation or court decree to which it or its property or assets may be subject or has
failed to obtain any license, permit, certificate, franchise or other governmental authorization or permit necessary to the ownership of its property or to the conduct of its business except, with respect to clauses (ii)&nbsp;and (iii), such
defaults or violations as would not have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) The Company and each of its subsidiaries
(i)&nbsp;make and keep accurate books and records and (ii)&nbsp;maintain internal accounting controls which provide reasonable assurance that (A)&nbsp;transactions are executed in accordance with management&#146;s authorization,
(B)&nbsp;transactions are recorded as necessary to permit preparation of their respective financial statements in conformity with generally accepted accounting principles in the United States and to maintain accountability for its assets,
(C)&nbsp;access to its assets is permitted only in accordance with management&#146;s authorization and (D)&nbsp;the reported accountability for their respective assets is compared with existing assets at reasonable intervals. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) The Company and each of its subsidiaries are in compliance with all applicable federal and state statutes, regulations,
rules and orders relating to the environmental protection or the protection of human health, in each case with such exceptions as would not have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) None of the Company or any of its subsidiaries is an &#147;investment company&#148; (as such term is used under the
Investment Company Act of 1940, as amended (the &#147;Investment Company Act&#148;), and the rules and regulations of the Commission thereunder). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Company, each of its directors and officers (as it relates to the Company) and its subsidiaries are in compliance with
the applicable provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations of the Commission adopted pursuant thereto, including the provisions of Section&nbsp;404 thereof, in each case with such exceptions as would not have a
Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) No forward-looking statement (within the meaning of Section&nbsp;27A of the Securities Act
and Section&nbsp;21E of the Exchange Act) contained in the Pricing Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) None of the Company, any of its subsidiaries or, to the Company&#146;s knowledge, any director, officer, agent, employee
or affiliate of the Company or any of its subsidiaries (acting on behalf of the Company or any of its subsidiaries, as applicable)&nbsp;(i) has used any funds for any unlawful contribution, gift, entertainment or other unlawful
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
expense relating to political activity; (ii)&nbsp;has made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any
foreign or domestic government or regulatory official or employee, including of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the
foregoing, or any political party or party official or candidate for political office; (iii)&nbsp;is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of either (x)&nbsp;the Foreign Corrupt
Practices Act of 1977, as amended, and the rules and regulations thereunder (the &#147;FCPA&#148;), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer,
payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any &#147;foreign official&#148; (as such term is defined in the FCPA) or any
foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA or (y)&nbsp;the U.K. Bribery Act 2010 (the &#147;Bribery Act&#148;), and the Company, its subsidiaries and, to the Company&#146;s
knowledge, the Company&#146;s affiliates have conducted their businesses in compliance with the FCPA and the Bribery Act and have instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to
ensure, continued compliance therewith or (iv)&nbsp;has made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback
or other unlawful or improper payment or benefit. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) The operations of the Company and its subsidiaries are and have
been conducted at all times in compliance in all material respects with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all
applicable jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental agency (collectively, the &#147;Money Laundering Laws&#148;) and no
action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries, with respect to the Money Laundering Laws is pending or, to the Company&#146;s knowledge,
threatened. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) None of the Company, any of its subsidiaries or, to the Company&#146;s knowledge, any director, officer,
agent, employee, affiliate or representative of the Company, any of its subsidiaries (acting on behalf of the Company or any of its subsidiaries, as applicable) is an individual or entity (&#147;Person&#148;) currently the subject or target of any
sanctions administered or enforced by the United States Government, including, without limitation, the U.S. Department of the Treasury&#146;s Office of Foreign Assets Control (&#147;OFAC&#148;), or other relevant sanctions authority (collectively,
&#147;Sanctions&#148;), nor is the Company or any of its subsidiaries, located, organized or resident in a country or territory that is the subject of Sanctions; and the Company will not directly or indirectly use the proceeds of the sale of the
Notes, or lend, contribute or otherwise make available such proceeds to any subsidiaries, joint venture partners or other Person, to fund any activities of or business with any Person, or in any country or territory, that, at the time of such
funding, is the subject of Sanctions or in any other manner that will result in a violation by any Person (including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of this Section&nbsp;1 as well as for Section&nbsp;7 hereof, references to &#147;the
Preliminary Prospectus and the Prospectus&#148; or to &#147;the Pricing Disclosure Package and the Prospectus&#148; are to each of such prospectuses (or, in the case of the Pricing Disclosure Package, the Preliminary Prospectus included therein) as
a separate or stand-alone document (and not the two such prospectuses taken together). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <I>Purchase of the Notes by the Underwriters.
</I>On the basis of the representations and warranties contained in, and subject to the terms and conditions of, this Agreement, the Company agrees to issue and sell to the several Underwriters and each of the Underwriters, severally and not
jointly, agrees to purchase from the Company, (i)&nbsp;at a purchase price of 99.734% of the principal amount thereof, plus accrued interest, if any, from March&nbsp;13, 2023, the respective amount of the $500,000,000 aggregate principal amount of
the 2026 Notes set forth opposite that Underwriter&#146;s name in Schedule 1 hereto and (ii)&nbsp;at a purchase price of 95.556% of the principal amount thereof, plus accrued interest, if any, from March&nbsp;13, 2023, the respective amount of the
$750,000,000 aggregate principal amount of the 2053 Notes set forth opposite that Underwriter&#146;s name in Schedule 1 hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The
Company shall not be obligated to deliver any of the Notes to be delivered on the Delivery Date, except upon payment for all the Notes to be purchased on the Delivery Date as provided herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3. <I>Offering of the Notes by the Underwriters. </I>Upon authorization by the Representatives of the release of the Notes, the several
Underwriters propose to offer the Notes for sale upon the terms and conditions set forth in the Pricing Disclosure Package and Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company hereby acknowledges that (a)&nbsp;the purchase and sale of the Notes pursuant to this Agreement is an <FONT
STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transaction between the Company, on the one hand, and each Underwriter and any affiliate through which it may be acting, on the other, (b)&nbsp;the Underwriters are acting as principal
and not as an agent or fiduciary of the Company and (c)&nbsp;the Company&#146;s engagement of the Underwriters in connection with the offering and the process leading up to the offering is as independent contractors and not in any other capacity.
Furthermore, the Company agrees that it is solely responsible for making its own judgments in connection with the offering (irrespective of whether any of the Underwriters has advised or is currently advising the Company on related or other
matters). The Company agrees that it will not claim that the Underwriters have rendered advisory services of any nature or respect, or owe an agency, fiduciary or similar duty to the Company, in connection with such transaction or the process
leading thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4. <I>Delivery of and Payment for the Notes.</I> Delivery of and payment for the Notes shall be made at the office of
Simpson Thacher&nbsp;&amp; Bartlett LLP, at 10:00 A.M., New York City time, on March&nbsp;13, 2023 or at such other date or place as shall be determined by agreement between the Representatives and the Company. This date and time are sometimes
referred to as the &#147;Delivery Date.&#148; On the Delivery Date, the Company shall deliver or cause to be delivered the Notes evidenced by one or more global securities registered in the name of Cede&nbsp;&amp; Co. as nominee of The Depository
Trust Company (&#147;DTC&#148;) for the account of the Underwriters against </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payment to or upon the order of the Company of the purchase price by wire transfer in immediately available funds. Time shall be of the essence, and delivery at the time and place specified
pursuant to this Agreement is a further condition of the obligation of each Underwriter hereunder. The Company shall make the Notes available for inspection by the Representatives in New York, New York, not later than 2:00 P.M., New York City time,
on the business day prior to the Delivery Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5. <I>Further Agreements of the Company.</I> The Company agrees: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) To prepare the Prospectus in a form approved by the Representatives and to file such Prospectus pursuant to Rule 424(b)
under the Securities Act not later than the Commission&#146;s close of business on the second business day following the execution and delivery of this Agreement or, if applicable, such earlier time as may be required by Rule 430A, Rule 430B or Rule
430C of the Rules and Regulations; to pay to the Commission the registration fees for the offering of the Notes within the time period required by Rule 456(b)(1)(i) of the Rules and Regulations, and in any event no later than one day prior to the
Delivery Date, and otherwise in accordance with Rule 456(b) and Rule 457(r) of the Rules and Regulations; to make no further amendment or any supplement to the Registration Statement or to the Prospectus prior to the Delivery Date except as
permitted herein; to advise the Representatives, promptly after it receives notice thereof, of the time when any amendment to the Registration Statement has been filed or becomes effective or any supplement to the Prospectus or any amended
Prospectus has been filed and to furnish the Representatives with copies thereof; to file promptly all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Sections 13(a),
13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus is required in connection with the offering or sale of the Notes; to advise the Representatives, promptly after it
receives notice thereof, of the issuance by the Commission of any stop order or of any order preventing or suspending the use of any Preliminary Prospectus, any Issuer Free Writing Prospectus or the Prospectus, of the suspension of the qualification
of the Notes for offering or sale in any jurisdiction, of the initiation or threatening of any proceeding for any such purpose, of any notice from the Commission objecting to the use of the form of the Registration Statement or any post-effective
amendment thereto pursuant to Rule 401(g)(2) of the Rules and Regulations, or of any request by the Commission for the amending or supplementing of the Registration Statement, any Issuer Free Writing Prospectus or the Prospectus or for additional
information; and, in the event of the issuance of any stop order or of any order preventing or suspending the use of any Preliminary Prospectus, any Issuer Free Writing Prospectus or the Prospectus or suspending any such qualification, to use
promptly its reasonable best efforts to obtain its withdrawal; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) To deliver promptly and without charge to the
Representatives such number of the following documents as the Representatives shall reasonably request: (A)&nbsp;conformed copies of the Registration Statement as originally filed with the Commission and each amendment thereto (in each case
excluding exhibits other than this Agreement and each Indenture), (B) each Preliminary Prospectus, the Prospectus and any amended or supplemented Prospectus, (C)&nbsp;each Issuer Free Writing Prospectus and (D)&nbsp;any document incorporated by
reference in the Prospectus (excluding exhibits thereto); and if the delivery </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
of a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) of the Rules and Regulations) is required at any time after the date hereof in connection with the offering or sale of
the Notes or any other securities relating thereto and if at such time any events shall have occurred as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state any
material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, when such Prospectus (or in lieu thereof, the notice referred to in Rule 173(a) of the Rules and Regulations) is delivered,
not misleading, or, if for any other reason it shall be necessary to amend or supplement the Prospectus or to file under the Exchange Act any document incorporated by reference in the Prospectus in order to comply with the Securities Act or the
Exchange Act, to notify the Representatives and, upon their reasonable request, to prepare and furnish without charge to each Underwriter and to any dealer in securities as many copies as the Representatives may from time to time reasonably request
of an amended or supplemented Prospectus which will correct such statement or omission or effect such compliance or to file such document; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) To file promptly with the Commission any amendment to the Registration Statement or the Prospectus or any supplement to the
Prospectus that may, in the reasonable judgment of the Company or the Representatives, be required by the Securities Act or requested by the Commission; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Prior to filing with the Commission any amendment to the Registration Statement or the Prospectus or supplement to the
Prospectus, any document incorporated by reference in the Prospectus or any Prospectus pursuant to Rule 424 of the Rules and Regulations, to furnish a copy thereof to the Representatives and Simpson Thacher&nbsp;&amp; Bartlett LLP, as counsel for
the Underwriters, and obtain the consent of the Representatives to the filing of such amendment or supplement, as applicable (such consent not to be unreasonably withheld); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) That, unless it has obtained or will obtain the prior written consent of the Representatives, it has not made and will not
make any offer relating to the Notes that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a &#147;free writing prospectus&#148; (as defined in Rule 405 of the Rules and Regulations) that would require filing
with the Commission, other than the information contained in the final term sheet prepared and filed pursuant to Section&nbsp;5(f); provided that the prior written consent of the parties hereto shall be deemed to have been given in respect of any
other free writing prospectuses identified on Schedule 2 hereto. Any such other free writing prospectus consented to by the Representatives is hereinafter referred to as a &#147;Permitted Free Writing Prospectus.&#148; The Company agrees that
(x)&nbsp;it has treated and will treat, as the case may be, each Permitted Free Writing Prospectus as an Issuer Free Writing Prospectus (and that each such Permitted Free Writing Prospectus shall be deemed to be an Issuer Free Writing Prospectus for
the purposes of this Agreement) and (y)&nbsp;it has complied and will comply, as the case may be, with the requirements of Rules 164 and 433 of the Rules and Regulations applicable to any Permitted Free Writing Prospectus, including in respect of
timely filing with the Commission, legending and record keeping; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) To file a final term sheet for the 2026 Notes and the 2053 Notes,
containing solely a description of final terms of the Notes and the offering thereof, substantially in the form of Exhibit A hereto, pursuant to Rule 433(d) of the Rules and Regulations within the time frame required by such Rule; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) If, at any time prior to the filing of a final prospectus pursuant to Rule 424(b), any event occurs as a result of which
the Pricing Disclosure Package or any Issuer Free Writing Prospectus would include any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein, in light of the circumstances under which they
were made at such time not misleading, to: (i)&nbsp;notify promptly the Representatives so that any use of the Pricing Disclosure Package or such Issuer Free Writing Prospectus may cease until it is amended or supplemented; (ii)&nbsp;amend or
supplement the Pricing Disclosure Package or such Issuer Free Writing Prospectus to correct such statement or omission; and (iii)&nbsp;supply any amendment or supplement to the Underwriters in such quantities as the Representatives may reasonably
request; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) As soon as practicable, to make generally available to the Company&#146;s security holders and to deliver to
the Representatives an earnings statement of the Company and its subsidiaries (which need not be audited) complying with Section&nbsp;11(a) of the Securities Act and the Rules and Regulations (including, at the option of the Company, Rule 158 of the
Rules and Regulations); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) For so long as any of the Notes are outstanding, to furnish and deliver without charge to the
Representatives and the Trustee, copies of all materials furnished or otherwise made available by the Company to its stockholders and all public reports and all reports and financial statements furnished by the Company to any national securities
exchange pursuant to the requirements of or agreements with such exchange or to the Commission pursuant to the Exchange Act or any rule or regulation of the Commission thereunder (such materials, reports and financial statements collectively, the
&#147;Reports&#148;); provided, however, that the obligations of the Company shall be considered satisfied for the purposes of this Section&nbsp;5(i) so long as the Company shall file such Reports electronically with the Commission pursuant to
Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> under the Rules and Regulations, and such Reports shall be publicly available; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) Promptly from time to time to take such action as the Representatives may reasonably request to qualify the Notes for
offering and sale under the securities laws of such jurisdictions as the Representatives may reasonably request and to comply with such laws so as to permit the continuance of sales and dealings therein in such jurisdictions for as long as may be
necessary to complete the distribution of the Notes; provided that, in connection therewith, the Company shall not be required to qualify as a foreign corporation or to file a general consent to service of process in any jurisdiction; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) For the period from the date of the Prospectus until the Delivery Date, not to, directly or indirectly, offer for sale,
sell, grant any option to purchase, issue or otherwise transfer or dispose of (or enter into any transaction or device which is designed to, or could be expected to, result in the disposition by any person at any time in the future of) any debt
securities of, or guaranteed by, any of the Company or its subsidiaries which are substantially similar to the Notes (other than the Notes), in each case, without the prior written consent of the Representatives; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) To apply the net proceeds from the sale of the Notes being sold by the
Company as set forth in the Pricing Disclosure Package and the Prospectus; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) To take such steps as shall be necessary to
ensure that neither the Company nor any subsidiary shall become an &#147;investment company&#148; (as such term is used under the Investment Company Act and the rules and regulations of the Commission thereunder); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) To not take, directly or indirectly, any action which is designed to stabilize or manipulate, or which constitutes or which
might reasonably be expected to cause or result in stabilization or manipulation, of the price of any security of the Company in connection with the offering of the Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6. <I>Expenses.</I> The Company agrees to pay (a)&nbsp;the costs incident to the authorization, issuance, sale and delivery of the Notes and
any taxes payable in connection therewith; (b)&nbsp;the costs incident to the preparation, printing and filing under the Securities Act of the Registration Statement and exhibits thereto, any Preliminary Prospectus, any Issuer Free Writing
Prospectus, the Prospectus and any amendment or supplement thereto; (c)&nbsp;the costs of distributing the Registration Statement as originally filed and each amendment thereto and any <FONT STYLE="white-space:nowrap">post-effective</FONT>
amendments thereof (including, in each case, exhibits), any Preliminary Prospectus, any Issuer Free Writing Prospectus, the Prospectus and any amendment or supplement to the Prospectus or any document incorporated by reference therein, all as
provided in this Agreement; (d)&nbsp;the costs of producing and distributing this Agreement and any other related documents in connection with the offering, purchase, sale and delivery of the Notes; (e)&nbsp;any applicable listing or similar fees;
(f)&nbsp;the fees and expenses of Fried, Frank, Harris, Shriver&nbsp;&amp; Jacobson LLP, counsel to the Company, and of PricewaterhouseCoopers LLP; (g)&nbsp;if applicable, the fees and expenses of qualifying the Notes under the securities laws of
the several jurisdictions as provided in Section&nbsp;5(j) of this Agreement, including, without limitation, the cost of preparing any Blue Sky application or other document prepared or executed by the Company (or based upon any written information
furnished by the Company for use therein) specifically for the purpose of qualifying any or all of the Notes under the securities laws of any state or other jurisdiction (any such application, document or information, a &#147;Blue Sky
Application&#148;) and of preparing, printing and distributing a Blue Sky Memorandum (including related fees and expenses of Simpson Thacher&nbsp;&amp; Bartlett LLP, counsel to the Underwriters); (h) the cost of &#147;road show&#148; presentation
materials; and (i)&nbsp;all other costs and expenses incident to the performance of the obligations of the Company under this Agreement; provided that, except as provided in Section&nbsp;8 and in Section&nbsp;11, the Underwriters shall pay their own
costs and expenses, including the costs and expenses of their counsel, any transfer taxes on the Notes which they may sell and the expenses of advertising any offering of the Notes made by the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7. <I>Conditions of Underwriters</I><I>&#146;</I><I> Obligations</I>. The respective obligations of the Underwriters hereunder are subject to
the accuracy, when made and on the Delivery Date, of the representations and warranties of the Company contained herein, to the performance by the Company of its obligations hereunder, and to each of the following additional terms and conditions:
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Prospectus shall have been timely filed with the Commission in
accordance with Section&nbsp;5(a); the Company shall have complied with all filing requirements applicable to any Issuer Free Writing Prospectus; no stop order suspending the effectiveness of the Registration Statement or any part thereof or
preventing or suspending the use of the Prospectus or any Issuer Free Writing Prospectus shall have been issued and no proceeding for that purpose shall have been initiated or threatened by the Commission; any request of the Commission for inclusion
of additional information in the Registration Statement or the Prospectus or otherwise shall have been complied with; and the Commission shall not have notified the Company of any objection to the use of the form of the Registration Statement
pursuant to Rule 401(g)(2) of the Rules and Regulations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) No Underwriter shall have discovered and disclosed to the
Company on or prior to the Delivery Date that the Registration Statement, the Pricing Disclosure Package or the Prospectus, or any amendment or supplement thereto contains an untrue statement of a fact which, in the opinion of Simpson
Thacher&nbsp;&amp; Bartlett LLP, counsel for the Underwriters, is material or omits to state a fact which, in the opinion of such counsel, is material and is required to be stated therein or is necessary to make the statements therein not
misleading. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) The Company shall have furnished to Simpson Thacher&nbsp;&amp; Bartlett LLP, counsel for the Underwriters,
all documents and information that they may reasonably request to enable them to pass upon all corporate proceedings and other legal matters incident to the authorization, form and validity of this Agreement, the Indentures, the Notes, the
Registration Statement, any Issuer Free Writing Prospectus, the Pricing Disclosure Package and the Prospectus, and all other legal matters relating to this Agreement and the transactions contemplated hereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Representatives shall have received from Simpson Thacher&nbsp;&amp; Bartlett LLP, counsel for the Underwriters, such
opinion letter or letters, dated as of the Delivery Date, with respect to the issuance and sale of the Notes, the Registration Statement, the Pricing Disclosure Package, the Prospectus and other related matters as the Representatives may reasonably
require. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Fried, Frank, Harris, Shriver&nbsp;&amp; Jacobson LLP, counsel to the Company, shall have furnished to the
Representatives its written opinion letter, addressed to the Underwriters and dated the Delivery Date, in form and substance reasonably satisfactory to the Representatives and substantially in the form of Exhibit B attached hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) Joseph C. Ventura, Chief Legal Officer to the Company, shall have furnished to the Representatives his written opinion
letter, addressed to the Underwriters and dated the Delivery Date, in form and substance reasonably satisfactory to the Representatives and substantially in the form of Exhibit C attached hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) Concurrently with the execution of this Agreement, the Representatives
shall have received from PricewaterhouseCoopers LLP a letter, in form and substance reasonably satisfactory to the Representatives, addressed to the Underwriters and dated the date hereof (i)&nbsp;confirming that it is an independent registered
public accounting firm within the meaning of the Securities Act and the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and is in compliance with the applicable
requirements relating to the qualification of accountants under Rule <FONT STYLE="white-space:nowrap">2-01</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> of the Commission, and (ii)&nbsp;stating, as of the date hereof (or, with
respect to matters involving changes or developments since the respective dates as of which specified financial information is given in the most recent Preliminary Prospectus, as of a date not more than five days prior to the date hereof), the
conclusions and findings of such firm with respect to the financial information contained in such Preliminary Prospectus and other matters ordinarily covered by accountants&#146; &#147;comfort letters&#148; to underwriters in connection with
registered public offerings. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) With respect to the letter of PricewaterhouseCoopers LLP referred to in the preceding
paragraph and delivered to the Representatives concurrently with the execution of this Agreement (the &#147;initial letter&#148;), the Company shall have furnished to the Representatives a letter (the &#147;bring-down letter&#148;) of such
accountants, addressed to the Underwriters and dated the Delivery Date (i)&nbsp;confirming that it is an independent registered public accounting firm within the meaning of the Securities Act and the applicable rules and regulations adopted by the
Commission and the Public Company Accounting Oversight Board (United States) and is in compliance with the applicable requirements relating to the qualification of accountants under Rule <FONT STYLE="white-space:nowrap">2-01</FONT> of Regulation <FONT
STYLE="white-space:nowrap">S-X</FONT> of the Commission, (ii)&nbsp;stating, as of the date of the bring-down letter (or, with respect to matters involving changes or developments since the respective dates as of which specified financial information
is given in the Prospectus, as of a date not more than five days prior to the date of the bring-down letter), the conclusions and findings of such firm with respect to the financial information contained in the Prospectus and other matters of the
type covered by the initial letter and (iii)&nbsp;confirming in all material respects the conclusions and findings set forth in the initial letter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company shall have furnished to the Representatives a certificate, dated the Delivery Date, of its President and Chief
Executive Officer, and its Chief Financial Officer stating that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The representations, warranties and agreements of the
Company in Section&nbsp;1 of this Agreement that are qualified as to materiality are true and correct as of the Delivery Date and the representations, warranties and agreements of the Company in Section&nbsp;1 that are not qualified as to
materiality are true and correct in all material respects as of the Delivery Date; the Company has complied with all its agreements contained herein; and the conditions set forth in Section&nbsp;7(a) and (j)&nbsp;have been fulfilled;<SUP
STYLE="font-size:75%; vertical-align:top"> </SUP>and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) They have carefully examined the Registration Statement, the Pricing
Disclosure Package and the Prospectus and, in their opinion (A)&nbsp;as of (1)&nbsp;each applicable Effective Date the Registration Statement did not, (2)&nbsp;the Time of Sale the Pricing Disclosure Package did not, and as of the Delivery Date the
Pricing Disclosure Package does not, and (3)&nbsp;its date the Prospectus did not, and as of the Delivery Date the Prospectus does not, in each case, include any untrue statement of a material fact and did not omit to state a material fact required
to be stated therein or necessary to make the statements therein (except in the case of the Registration Statement, in light of the circumstances under which they were made) not misleading, and (B)&nbsp;since the applicable Effective Date no event
has occurred which should have been set forth in a supplement or amendment to the Registration Statement which was not so set forth. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) (i) Neither the Company nor any of its subsidiaries shall have sustained since the date of the latest audited financial
statements included or incorporated by reference in the Preliminary Prospectus any loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or
governmental action, order or decree, otherwise than as set forth in the Preliminary Prospectus and the Prospectus or (ii)&nbsp;since such date there shall not have been any change in the capital stock or long-term debt of the Company or any of its
subsidiaries or any change, in or affecting the business, properties, results of operations, financial condition or prospects of the Company and its subsidiaries, taken as a whole, otherwise than as set forth in the Preliminary Prospectus and the
Prospectus, the effect of which, in any such case described in clause (i)&nbsp;or (ii), is, in the judgment of the Representatives, so material and adverse as to make it impracticable or inadvisable to proceed with the public offering or the
delivery of the Notes being delivered on the Delivery Date on the terms and in the manner contemplated in the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) Subsequent to the execution and delivery of this Agreement (i)&nbsp;no downgrading shall have occurred in the rating
accorded the Company&#146;s debt securities by any &#147;nationally recognized statistical rating organization&#148;, as that term is defined in Section&nbsp;3(a)(62) of the Exchange Act and (ii)&nbsp;no such organization shall have publicly
announced that it has under surveillance or review, with possible negative implications, its rating of any of the Company&#146;s debt securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) Subsequent to the execution and delivery of this Agreement there shall not have occurred any of the following:
(i)&nbsp;trading in securities generally on the New York Stock Exchange or in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, or trading in any securities issued or guaranteed by the
Company on any exchange or in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market, shall have been suspended or materially limited or minimum prices shall have been established on any such
exchange or such market by the Commission, by such exchange or by any other regulatory body or governmental authority having jurisdiction, (ii)&nbsp;a banking moratorium shall have been declared by federal or New York state authorities, (iii)&nbsp;a
material disruption in commercial banking or securities settlement or clearance services has occurred, or (iv)&nbsp;there shall have been a declaration of a national emergency or war by the United States or there shall have occurred any outbreak or
escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States, that, in the judgment of the Representatives, is material and adverse and makes it impracticable or inadvisable to
proceed with the public offering, sale or delivery of the Notes being delivered on the Delivery Date on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) No default or event which, with notice or lapse of time or both, would
constitute such a default shall have occurred and be continuing, or would result from the transactions contemplated hereby prior to, concurrently with or immediately following the consummation of the offering of the Notes under any of the
Indentures. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) The Company and the Trustee shall have entered into each Indenture, and the Underwriters shall have
received counterparts, conformed as executed, thereof, and the Notes shall have been duly executed and delivered by the Company and authenticated by the Trustee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">All opinions, letters, evidence and certificates mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the
provisions hereof only if they are in form and substance reasonably satisfactory to Simpson Thacher&nbsp;&amp; Bartlett LLP, counsel for the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8. <I>Indemnification and Contribution.</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company<B> </B>shall indemnify and hold harmless each Underwriter, its directors, officers, employees, agents and
affiliates, and each person, if any, who controls any Underwriter within the meaning of the Securities Act, from and against any loss, claim, damage or liability, joint or several, or any action in respect thereof (including, but not limited to, any
loss, claim, damage, liability or action relating to purchases and sales of the Notes), to which that Underwriter, director, officer, employee, agent, affiliate or controlling person may become subject, under the Securities Act or otherwise, insofar
as such loss, claim, damage, liability or action arises out of, or is based upon, (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, any Issuer Free Writing Prospectus, any
Preliminary Prospectus or the Prospectus or in any amendment or supplement thereto (ii)&nbsp;the omission or alleged omission to state in the Registration Statement, any Issuer Free Writing Prospectus, any Preliminary Prospectus or the Prospectus,
or in any amendment or supplement thereto any material fact required to be stated therein or necessary to make the statements therein not misleading or (iii)&nbsp;any act or failure to act or any alleged act or failure to act by any Underwriter in
connection with, or relating in any manner to, the Notes or the offering contemplated hereby, and which is included as part of or referred to in any loss, claim, damage, liability or action arising out of or based upon matters covered by clause
(i)&nbsp;or (ii) above (provided<I> </I>that the Company shall not be liable under this clause (iii)&nbsp;to the extent that it is determined in a final judgment by a court of competent jurisdiction that such loss, claim, damage, liability or action
resulted directly from any such acts or failures to act undertaken or omitted to be taken by such Underwriter through its negligence or willful misconduct), and shall reimburse each Underwriter and each such director, officer, employee, agent,
affiliate or controlling person promptly upon demand for any legal or other expenses reasonably incurred by that Underwriter, director, officer, employee, agent, affiliate or controlling person in connection with investigating or defending or
preparing to defend against any such loss, claim, damage, liability or action as such expenses are incurred; provided, however, that the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Company shall not be liable in any such case to the extent that any such loss, claim, damage, liability or action arises out of, or is based upon, any untrue statement or alleged untrue statement
or omission or alleged omission made in the Registration Statement, any Issuer Free Writing Prospectus, any Preliminary Prospectus or the Prospectus, or in any such amendment or supplement, in reliance upon and in conformity with the
Underwriters&#146; Information. The foregoing indemnity agreement is in addition to any liability that the Company may otherwise have to any Underwriter or to any director, officer, employee, agent, affiliate or controlling person of that
Underwriter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) Each Underwriter, severally and not jointly, shall indemnify and hold harmless the Company, its
directors, officers and employees, and each person, if any, who controls the Company within the meaning of the Securities Act, from and against any loss, claim, damage or liability, joint or several, or any action in respect thereof, to which the
Company or any such director, officer, employee or controlling person may become subject, under the Securities Act or otherwise, insofar as such loss, claim, damage, liability or action arises out of, or is based upon, (i)&nbsp;any untrue statement
or alleged untrue statement of a material fact contained in any Issuer Free Writing Prospectus, any Preliminary Prospectus or the Prospectus or in any amendment or supplement thereto or (ii)&nbsp;the omission or alleged omission to state in any
Issuer Free Writing Prospectus, any Preliminary Prospectus or the Prospectus, or in any amendment or supplement thereto any material fact required to be stated therein or necessary to make the statements therein not misleading, but in each case only
to the extent that the untrue statement or alleged untrue statement or omission or alleged omission was made in reliance upon and in conformity with the Underwriters&#146; Information, and shall reimburse the Company and any such director, officer,
employee or controlling person for any legal or other expenses reasonably incurred by the Company or any such director, officer, employee or controlling person in connection with investigating or defending or preparing to defend against any such
loss, claim, damage, liability or action as such expenses are incurred. The foregoing indemnity agreement is in addition to any liability that any Underwriter may otherwise have to the Company or any such director, officer, employee or controlling
person. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Promptly after receipt by an indemnified party under this Section&nbsp;8 of notice of any claim or the
commencement of any action, the indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under this Section&nbsp;8, notify the indemnifying party in writing of the claim or the commencement of that action;
provided, however, that the failure to notify the indemnifying party shall not relieve it from any liability which it may have under this Section&nbsp;8 except to the extent it has been materially prejudiced by such failure; and, provided further,
that the failure to notify the indemnifying party shall not relieve it from any liability which it may have to an indemnified party otherwise than under this Section&nbsp;8. If any such claim or action shall be brought against an indemnified party,
and it shall notify the indemnifying party thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it wishes, jointly with any other similarly notified indemnifying party, to assume the defense thereof with
counsel reasonably satisfactory to the indemnified party. After notice from the indemnifying party to the indemnified party of its election to assume the defense of such claim or action, the indemnifying party shall not be liable to the indemnified
party under this Section&nbsp;8 for any legal or other expenses subsequently incurred by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
indemnified party in connection with the defense thereof other than reasonable costs of investigation; provided, however, that the Representatives shall have the right to employ counsel to
represent jointly the Representatives and those other Underwriters and their respective directors, officers, employees, agents, affiliates and controlling persons who may be subject to liability arising out of any claim in respect of which indemnity
may be sought by the Underwriters against the Company under this Section&nbsp;8 if, in the reasonable judgment of the Representatives, it is advisable for the Representatives and those Underwriters, directors, officers, employees, agents, affiliates
and controlling persons to be jointly represented by separate counsel, and in that event the fees and expenses of such separate counsel shall be paid by the Company. No indemnifying party shall (i)&nbsp;without the prior written consent of the
indemnified parties (which consent shall not be unreasonably withheld), settle or compromise or consent to the entry of any judgment with respect to any pending or threatened claim, action, suit or proceeding in respect of which indemnification or
contribution may be sought hereunder (whether or not the indemnified parties are actual or potential parties to such claim or action) unless such settlement, compromise or consent includes an unconditional release of each indemnified party from all
liability arising out of such claim, action, suit or proceeding, or (ii)&nbsp;be liable for any settlement of any such action effected without its written consent (which consent shall not be unreasonably withheld), but if settled with the consent of
the indemnifying party or if there be a final judgment of the plaintiff in any such action, the indemnifying party agrees to indemnify and hold harmless any indemnified party from and against any loss or liability by reason of such settlement or
judgment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) If the indemnification provided for in this Section&nbsp;8 shall for any reason be unavailable to or
insufficient to hold harmless an indemnified party under Section&nbsp;8(a) or 8(b) in respect of any loss, claim, damage or liability, or any action in respect thereof, referred to therein, then each indemnifying party shall, in lieu of indemnifying
such indemnified party, contribute to the amount paid or payable by such indemnified party as a result of such loss, claim, damage or liability, or action in respect thereof, (i)&nbsp;in such proportion as shall be appropriate to reflect the
relative benefits received by the Company on the one hand and the Underwriters on the other from the offering of the Notes or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;above is not permitted by applicable law, in such proportion as is
appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;above but also the relative fault of the Company on the one hand and the Underwriters on the other with respect to the statements or omissions which resulted in
such loss, claim, damage or liability, or action in respect thereof, as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other with respect to such
offering shall be deemed to be in the same proportion as the total net proceeds from the offering of the Notes purchased under this Agreement (before deducting expenses) received by the Company, on the one hand, and the total underwriting discounts
and commissions received by the Underwriters with respect to the Notes purchased under this Agreement, on the other hand, bear to the total gross proceeds from the offering of the Notes under this Agreement, in each case as set forth in the table on
the cover page of the Prospectus. The relative fault shall be determined by reference to whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by
the Company or the Underwriters, the intent of the parties and their relative knowledge, access to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
information and opportunity to correct or prevent such statement or omission. The Company and the Underwriters agree that it would not be just and equitable if contributions pursuant to this
Section&nbsp;8 were to be determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take into account the equitable considerations referred to herein.
The amount paid or payable by an indemnified party as a result of the loss, claim, damage or liability, or action in respect thereof, referred to above in this Section&nbsp;8 shall be deemed to include, for purposes of this Section&nbsp;8, any legal
or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section&nbsp;8, no Underwriter shall be required to contribute any amount
in excess of the amount by which the total price at which the Notes underwritten by it and distributed to the public was offered to the public exceeds the amount of any damages which such Underwriter has otherwise paid or become liable to pay by
reason of any untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who
was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations to contribute as provided in this Section&nbsp;8 are several in proportion to their respective underwriting obligations and not joint. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Underwriters severally confirm and the Company acknowledges that the statements with respect to the public offering of
the Notes by the Underwriters set forth in the fifth paragraph, the third sentence of the seventh paragraph and the eighth, ninth and tenth paragraphs<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>under the caption &#147;Underwriting
(Conflicts of Interest)&#148; in the Prospectus Supplement are correct and constitute the only information concerning such Underwriters furnished in writing to the Company through the Representatives by or on behalf of the Underwriters specifically
for inclusion in the Pricing Disclosure Package, any Issuer Free Writing Prospectus or the Prospectus (the &#147;Underwriters&#146; Information&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9. <I>Defaulting Underwriters</I>. If, on the Delivery Date, any Underwriter defaults in the performance of its obligations under this
Agreement, the remaining <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters shall be obligated to purchase the Notes which the defaulting Underwriter agreed but failed to purchase on the Delivery Date in the respective proportions
which the aggregate principal amount of Notes set opposite the name of each remaining <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter in Schedule 1 hereto bears to the total aggregate principal amount of Notes set opposite the
names of all the remaining <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters in Schedule 1 hereto; provided, however, that the remaining <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters shall not be obligated to
purchase any of the Notes on the Delivery Date if the total aggregate principal amount of Notes which the defaulting Underwriter or Underwriters agreed but failed to purchase on such date exceeds 9.09% of the total aggregate principal amount of
Notes to be purchased on the Delivery Date, and any remaining <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter shall not be obligated to purchase more than 110% of the aggregate principal amount of Notes which it agreed to purchase
on the Delivery Date pursuant to the terms of Section&nbsp;2. If the foregoing maximums are exceeded, the remaining <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters, or those other underwriters satisfactory to the Representatives
who so agree, shall have the right, but shall not be obligated, to purchase, in such proportion as may be agreed upon among them, all the Notes to be purchased on the Delivery Date. If the remaining Underwriters or other underwriters satisfactory to
the Representatives do not elect to purchase Notes which the defaulting Underwriter or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Underwriters agreed but failed to purchase on the Delivery Date, this Agreement shall terminate without liability on the part of any <FONT STYLE="white-space:nowrap">non-defaulting</FONT>
Underwriter or the Company, except that the Company will continue to be liable for the payment of expenses of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to the extent set forth in Sections 6 and 11. As used in this
Agreement, the term &#147;Underwriter&#148; includes, for all purposes of this Agreement unless the context requires otherwise, any party not listed in Schedule 1 hereto who, pursuant to this Section&nbsp;9, purchases the Notes which a defaulting
Underwriter agreed but failed to purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Nothing contained herein shall relieve a defaulting Underwriter of any liability it may have
to the Company for damages caused by its default. If other underwriters are obligated or agree to purchase the Notes of a defaulting or withdrawing Underwriter, either the Representatives or the Company may postpone the Delivery Date for up to seven
full business days in order to effect any changes that in the opinion of counsel for the Company or counsel for the Underwriters may be necessary in the Registration Statement, the Prospectus or in any other document or arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10. <I>Termination.</I> The obligations of the Underwriters hereunder may be terminated by the Representatives by notice given to and received
by the Company prior to delivery of and payment for the Notes if, prior to that time, (i)&nbsp;any of the events described in Sections 7(j), 7(k) and 7(l) shall have occurred, (ii)&nbsp;the representation in Section&nbsp;1(g) is incorrect in any
respect, or (iii)&nbsp;the Underwriters shall decline to purchase the Notes for any reason permitted under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.
<I>Reimbursement of Underwriters</I><I>&#146;</I><I> Expenses.</I> If the Company shall fail to tender the Notes for delivery to the Underwriters by reason of any failure, refusal or inability on the part of the Company to perform any agreement on
its part to be performed (other than with respect to a termination pursuant to clause (ii)&nbsp;of Section&nbsp;10 if the Company and the Underwriters subsequently enter into another agreement for the Underwriters to underwrite the same or
substantially similar securities of the Company), or because any other condition of the Underwriters&#146; obligations hereunder required to be fulfilled by the Company is not fulfilled, the Company will reimburse the Underwriters for all reasonable
documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses (including fees and disbursements of counsel) incurred by the Underwriters in connection with this Agreement and the proposed purchase
of the Notes, and upon demand the Company shall pay the full amount thereof to the Representatives. If this Agreement is terminated pursuant to Section&nbsp;9 by reason of the default of one or more Underwriters, the Company shall not be obligated
to reimburse any defaulting Underwriter on account of those expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">12. <I>Notices, etc.</I> All statements, requests, notices and
agreements hereunder shall be in writing, and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) if to the Underwriters, shall be delivered or sent by mail, telex or
facsimile transmission to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Barclays Capital Inc., 745 Seventh Avenue, New York, New York 10019, Attention: Syndicate
Registration (Fax: (646) <FONT STYLE="white-space:nowrap">834-8133);</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Citigroup Global Markets Inc., 388 Greenwich Street, New York, New York
10013, Attention: General Counsel (Fax: (646) <FONT STYLE="white-space:nowrap">291-1469);</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Morgan
Stanley&nbsp;&amp; Co. LLC, 1585 Broadway, 29<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, New York, New York 10036, Attention: Investment Banking Division (Fax: (212) <FONT STYLE="white-space:nowrap">507-8999);</FONT> and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) U.S. Bancorp Investments, Inc., 214 North Tryon Street, 26th Floor, Charlotte, North Carolina 28202, Attention: Debt
Capital Markets (Fax: (704) <FONT STYLE="white-space:nowrap">335-2393)</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) Wells Fargo Securities, LLC, 550 South
Tryon Street, 5th Floor, Charlotte, North Carolina 28202, Attention: Transaction Management (Email: tmgcapitalmarkets@wellsfargo.com); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">in
each case with a copy to Simpson Thacher&nbsp;&amp; Bartlett LLP, 425 Lexington Avenue, New York, New York 10017, Attention: Mark Brod (Fax: (212) <FONT STYLE="white-space:nowrap">455-2502);</FONT> or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) if to the Company, shall be delivered or sent by mail, telex or facsimile transmission to the address of the Company set
forth in the Registration Statement, Attention: Chief Financial Officer (Fax: (502) <FONT STYLE="white-space:nowrap">580-3615),</FONT> with a copy to Fried, Frank, Harris, Shriver&nbsp;&amp; Jacobson LLP, One New York Plaza, New York, New York
10004, Attention: Joshua Wechsler (Fax: (212) <FONT STYLE="white-space:nowrap">859-4000).</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">13. <I>Persons Entitled to Benefit of
Agreement.</I> This Agreement shall inure to the benefit of and be binding upon the Underwriters, the Company, and their respective successors. This Agreement and the terms and provisions hereof are for the sole benefit of only those persons, except
that (A)&nbsp;the representations, warranties, indemnities and agreements of the Company contained in this Agreement shall also be deemed to be for the benefit of the person or persons, if any, who control any Underwriter within the meaning of
Section&nbsp;15 of the Securities Act and (B)&nbsp;the indemnity agreement of the Underwriters contained in Section&nbsp;8(b) of this Agreement shall be deemed to be for the benefit of directors of the Company, officers of the Company who have
signed the Registration Statement and any person controlling the Company within the meaning of Section&nbsp;15 of the Securities Act. Nothing in this Agreement is intended or shall be construed to give any person, other than the persons referred to
in this Section, any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">14. <I>Survival.</I> The respective indemnities, representations, warranties and agreements of the Company and the Underwriters contained in
this Agreement or made by or on behalf of them, respectively, pursuant to this Agreement, shall survive the delivery of and payment for the Notes and shall remain in full force and effect, regardless of any investigation made by or on behalf of any
of them or any person controlling any of them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">15. <I>Recognition of the U.S. Special Resolution Regimes.</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution
Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this
Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a
proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S.
Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) For purposes of this Section&nbsp;15, a &#147;BHC Act Affiliate&#148; has the meaning assigned to the term
&#147;affiliate&#148; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k). &#147;Covered Entity&#148; means any of the following: (i)&nbsp;a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance
with, 12 C.F.R. &#167; 252.82(b); (ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii)&nbsp;a &#147;covered FSI&#148; as that term is defined in, and interpreted in
accordance with, 12 C.F.R. &#167; 382.2(b). &#147;Default Right&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable. &#147;U.S. Special Resolution
Regime&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">16. <I>Definitions of &#147;Business Day&#148; and &#147;Subsidiary&#148;</I>. For purposes of this Agreement, (a) &#147;business day&#148;
means each Monday, Tuesday, Wednesday, Thursday or Friday which is not a day on which banking institutions in New York are generally authorized or obligated by law or executive order to close and (b) &#147;subsidiary&#148; has the meaning set forth
in Rule 405 of the Rules and Regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">17. <I>Governing Law.</I> <B>This Agreement shall be governed by, and construed in accordance
with, the laws of the State of New York.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">18. <I>Counterparts.</I> This Agreement may be executed in one or more counterparts and, if
executed in more than one counterpart, the executed counterparts shall each be deemed to be an original but all such counterparts shall together constitute one and the same instrument. The words &#147;executed,&#148; &#147;execution,&#148;
&#147;signed,&#148; &#147;signature,&#148; &#147;delivery,&#148; and words of like import in or relating to this Agreement or any document to be signed in connection with this Agreement shall be deemed to include electronic signatures, deliveries or
the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be,
and the parties hereto consent to conduct the transactions contemplated hereunder by electronic means. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">19. <I>Headings.</I> The headings herein are inserted for convenience of reference only and
are not intended to be part of, or to affect the meaning or interpretation of, this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature pages to follow</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If the foregoing correctly sets forth the agreement between the Company and the
Underwriters, please indicate your acceptance in the space provided for that purpose below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">H<SMALL>UMANA</SMALL> I<SMALL>NC</SMALL>.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Robert Marcoux</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Robert Marcoux</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: &nbsp;&nbsp;Vice President&nbsp;&amp; Treasurer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page to Humana
Underwriting Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">B<SMALL>ARCLAYS</SMALL> C<SMALL>APITAL</SMALL> I<SMALL>NC</SMALL>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ James Gutow</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: James Gutow</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: &nbsp;&nbsp;Managing Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For itself and as a Representative </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of the several Underwriters named </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in Schedule 1 hereto </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page to Humana
Underwriting Agreement] </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">C<SMALL>ITIGROUP</SMALL> G<SMALL>LOBAL</SMALL> M<SMALL>ARKETS</SMALL> I<SMALL>NC</SMALL>. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Brian D. Bednarski</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Brian D. Bednarski</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Managing Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For itself and as a Representative </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of the several Underwriters named </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in Schedule 1 hereto </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page to Humana Underwriting Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">M<SMALL>ORGAN</SMALL> S<SMALL>TANLEY</SMALL>&nbsp;&amp; C<SMALL>O</SMALL>. LLC </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Thomas Hadley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Thomas Hadley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Managing Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For itself and as a Representative </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of the several Underwriters named </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in Schedule 1 hereto </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page to Humana Underwriting Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. B<SMALL>ANCORP</SMALL> I<SMALL>NVESTMENTS</SMALL>, I<SMALL>NC</SMALL>. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ William J. Carney</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: William J. Carney</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Managing Director</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For itself and as a Representative </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of the several Underwriters named </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in Schedule 1 hereto </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page to Humana Underwriting Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">W<SMALL>ELLS</SMALL> F<SMALL>ARGO</SMALL> S<SMALL>ECURITIES</SMALL>, LLC </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Carolyn Hurley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Carolyn Hurley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Managing Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For itself and as a Representative </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of the several Underwriters named </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in Schedule 1 hereto </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page to Humana Underwriting Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>SCHEDULE 1 </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><BR>Underwriters</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Aggregate&nbsp;Principal<BR>Amount<BR>of 2026 Notes</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Aggregate&nbsp;Principal<BR>Amount<BR>of 2053 Notes</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Barclays Capital Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91,875,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91,875,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91,875,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Bancorp Investments, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91,875,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wells Fargo Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">91,875,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58,125,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PNC Capital Markets LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,875,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Truist Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,875,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BNY Mellon Capital Markets, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fifth Third Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">KeyBanc Capital Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mizuho Securities USA LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Regions Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scotia Capital (USA) Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SMBC Nikko Securities America, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TD Securities (USA) LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">UMB Financial Services, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Academy Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Drexel Hamilton, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Penserra Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Seelaus&nbsp;&amp; Co., LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,750,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">500,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">750,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>SCHEDULE 2 </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ISSUER FREE WRITING PROSPECTUSES </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(A) Issuer
Free Writing Prospectuses considered part of the Pricing Disclosure Package: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Term sheet substantially in the form of Exhibit A hereto </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(B) Issuer Free Writing Prospectuses not considered part of the Pricing Disclosure Package: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">None </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Filed Pursuant to Rule 433 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Registration Statement <FONT STYLE="white-space:nowrap">No.&nbsp;333-254041</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HUMANA INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>5.700</B>%
<B>Senior Notes due 2026 </B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>5.500</B>% <B>Senior Notes due 2053</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>February&nbsp;27, 2023 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Pricing Term Sheet </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Issuer:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Humana Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Ratings*:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">[Intentionally omitted]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Trade Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">February&nbsp;27, 2023</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Settlement Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">(T+10)<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> March&nbsp;13, 2023</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Active Bookrunners:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Barclays Capital Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Citigroup Global
Markets Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. Bancorp
Investments, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Wells Fargo Securities, LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Passive Bookrunners:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">BofA Securities, Inc. <BR>Goldman Sachs&nbsp;&amp; Co. LLC <BR>J.P. Morgan Securities LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><FONT STYLE="white-space:nowrap">Co-Managers:</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PNC Capital Markets LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Truist Securities,
Inc. <BR>BNY Mellon Capital Markets, LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fifth Third Securities, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KeyBanc Capital Markets Inc. <BR>Mizuho Securities USA LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regions Securities LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Scotia Capital (USA) Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SMBC Nikko Securities America, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TD Securities (USA) LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">UMB Financial Services, Inc. <BR>Academy Securities, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Drexel
Hamilton, LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Penserra Securities LLC</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">R. Seelaus&nbsp;&amp;
Co., LLC</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>2026 Notes </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Security Description:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Senior Notes due 2026</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Aggregate Principal Amount:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$500,000,000</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Coupon:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.700%</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Under Rule <FONT STYLE="white-space:nowrap">15c6-1</FONT> of the Securities Exchange Act of 1934, as amended,
trades in the secondary market generally are required to settle in two business days, unless the parties to such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the notes on any date prior to two business days before
delivery will be required, by virtue of the fact that the notes initially will settle in ten business days (T+10), to specify alternative settlement arrangements at the time of any such trade to prevent a failed settlement. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Maturity Date:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;13, 2026</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Price to Public:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.984% of the principal amount</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Benchmark Treasury:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">4.000% UST due February&nbsp;15, 2026</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Benchmark Treasury Price / Yield:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">98-19+</FONT> / 4.506%</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Spread to Benchmark Treasury:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">+120 bps</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Yield to Maturity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">5.706%</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Interest Payment Dates:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;13 and September&nbsp;13, commencing September&nbsp;13, 2023</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Optional Redemption:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Make-whole call at T+20 bps plus accrued and unpaid interest</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Par Call:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">On or after March&nbsp;13, 2024</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CUSIP/ISIN:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">444859BW1 / US444859BW11</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>2053 Notes </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Security Description:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Senior Notes due 2053</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Aggregate Principal Amount:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>$750,000,000</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Coupon:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.500%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Maturity Date:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March&nbsp;15, 2053</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Price to Public:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>96.431% of the principal amount</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Benchmark Treasury:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>4.000% UST due November&nbsp;15, 2052</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Benchmark Treasury Price / Yield:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">100-27</FONT> / 3.951%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Spread to Benchmark Treasury:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>+180 bps</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Yield to Maturity:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>5.751%</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Interest Payment Dates:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>March&nbsp;15 and September&nbsp;15, commencing September&nbsp;15, 2023</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Optional Redemption:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Make-whole call at T+30 bps plus accrued and unpaid interest</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Par Call:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>On or after September&nbsp;15, 2052</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>CUSIP/ISIN:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>444859BX9 / US444859BX93</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>*</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to
revision or withdrawal at any time.</B> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The issuer has filed a registration statement (including a prospectus) with the SEC for the
offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement, the preliminary prospectus supplement thereto relating to each series of notes offered hereby and other documents the
issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer
participating in the offering will arrange to send you the prospectus and the preliminary prospectus supplement thereto relating to each series of notes offered hereby if you request it by calling Barclays Capital Inc. toll-free at <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-888-603-5847,</FONT></FONT></FONT> Citigroup Global Markets Inc. toll-free at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-800-831-9146,</FONT></FONT></FONT> Morgan Stanley&nbsp;&amp; Co. LLC at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-866-718-1649,</FONT></FONT></FONT> U.S. Bancorp
Investments, Inc. toll-free at (877) <FONT STYLE="white-space:nowrap">558-2607</FONT> or Wells Fargo Securities, LLC toll-free at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-645-3751.</FONT></FONT></FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Any
disclaimer or other notice that may appear below is not applicable to this communication and should be disregarded. Such disclaimer or notice was automatically generated as a result of this communication being sent by Bloomberg or another email
system. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF OPINION OF FRIED, FRANK, HARRIS, SHRIVER&nbsp;&amp; JACOBSON LLP </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT C </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF OPINION OF JOSEPH C. VENTURA, CHIEF LEGAL OFFICER OF THE COMPANY </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d461254dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>news release</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:6.00em; font-size:10pt; font-family:Times New Roman">Humana Inc.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:6.00em; font-size:10pt; font-family:Times New Roman">500 West Main Street</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:6.00em; font-size:10pt; font-family:Times New Roman">P.O. Box 1438</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:6.00em; font-size:10pt; font-family:Times New Roman">Louisville, KY 40202</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">FOR MORE INFORMATION CONTACT:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lisa Stoner</TD>
<TD VALIGN="bottom" ROWSPAN="6">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ROWSPAN="6"> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g461254g0228134644724.jpg" ALT="LOGO">
</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Investor Relations</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Humana Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">502-580-2652</FONT></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">e-mail:</FONT> <U>lstamper@humana.com</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Mark Taylor</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Corporate Communications</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Humana Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">317-753-0345</FONT></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">e-mail:&nbsp;</FONT><U>mtaylor108@humana.com</U></P></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Humana Prices $1.25 Billion Debt Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Louisville, KY&#151;</B>February&nbsp;27, 2023&#151;Humana Inc. (the &#147;company&#148;) (NYSE: HUM) announced today that it has priced a public offering
of $1.25&nbsp;billion in aggregate principal amount of senior notes. These senior notes are comprised of $500&nbsp;million of the company&#146;s 5.700&nbsp;percent senior notes, due 2026, at 99.984&nbsp;percent of the principal amount and
$750&nbsp;million of the company&#146;s 5.500&nbsp;percent senior notes, due 2053, at 96.431&nbsp;percent of the principal amount (collectively, the &#147;Senior Notes Offerings&#148;). The Senior Notes Offerings are expected to close on
March&nbsp;13, 2023, subject to the satisfaction of customary closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company expects net proceeds from the Senior Notes Offerings will
be approximately $1.211&nbsp;billion after deducting underwriters&#146; discounts and estimated offering expenses. The company intends to use the net proceeds from the Senior Notes Offerings to repay outstanding amounts under its $500&nbsp;million
Delayed Draw Term Loan. Net proceeds from the Senior Notes Offerings in excess of the amount required to repay outstanding borrowings under its Delayed Draw Term Loan at the time the Senior Notes Offerings are completed will be used for general
corporate purposes, which may include the repayment of borrowings under its commercial paper program. As of December&nbsp;31, 2022, the outstanding balance under the company&#146;s Delayed Draw Term Loan was $500&nbsp;million and the interest rate
in effect on that outstanding balance was LIBOR plus 125 basis points. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Barclays Capital Inc., Citigroup Global Markets Inc., Morgan Stanley&nbsp;&amp;
Co. LLC, U.S. Bancorp Investments, Inc. and Wells Fargo Securities, LLC are acting as active joint book-running managers for the Senior Notes Offerings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Senior Notes Offerings are being made pursuant to an effective shelf registration statement (including a base prospectus) filed with the Securities and
Exchange Commission (the &#147;SEC&#148;). The Senior Notes Offerings may be made only by means of a prospectus and related prospectus supplement, copies of which may be obtained by calling Barclays Capital Inc. toll-free at <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-888-603-5847,</FONT></FONT></FONT> Citigroup Global Markets Inc. toll-free at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-800-831-9146,</FONT></FONT></FONT> Morgan Stanley&nbsp;&amp; Co. LLC at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-866-718-1649,</FONT></FONT></FONT> U.S. Bancorp
Investments, Inc. toll-free at (877) <FONT STYLE="white-space:nowrap">558-2607</FONT> or Wells Fargo Securities, LLC toll-free at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-645-3751.</FONT></FONT></FONT> An electronic copy of the registration statement and prospectus supplement, together with the base prospectus, is
available on the SEC&#146;s website at www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This news release does not constitute an offer to sell or a solicitation of an offer to buy the
securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such
jurisdiction. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Cautionary Statement </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This news release includes forward-looking statements regarding Humana within the meaning of the Private Securities Litigation Reform Act of 1995. When used in
investor presentations, press releases, SEC filings, and in oral statements made by or with the approval of one of Humana&#146;s executive officers, the words or phrases like &#147;expects,&#148; &#147;believes,&#148; &#147;anticipates,&#148;
&#147;intends,&#148; &#147;likely will result,&#148; &#147;estimates,&#148; &#147;projects&#148; or variations of such words and similar expressions are intended to identify such forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions, including, among other
things, information set forth in the &#147;Risk Factors&#148; section of the company&#146;s SEC filings, a summary of which includes but is not limited to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If Humana does not design and price its products properly and competitively, if the premiums Humana receives are
insufficient to cover the cost of healthcare services delivered to its members, if the company is unable to implement clinical initiatives to provide a better healthcare experience for its members, lower costs and appropriately document the risk
profile of its members, or if its estimates of benefits expense are inadequate, Humana&#146;s profitability could be materially adversely affected. Humana estimates the costs of its benefit expense payments, and designs and prices its products
accordingly, using actuarial methods and assumptions based upon, among other relevant factors, claim payment patterns, medical cost inflation, and historical developments such as claim inventory levels and claim receipt patterns. The company
continually reviews estimates of future payments relating to benefit expenses for services incurred in the current and prior periods and makes necessary adjustments to its reserves, including premium deficiency reserves, where appropriate. These
estimates involve extensive judgment, and have considerable inherent variability because they are extremely sensitive to changes in claim payment patterns and medical cost trends. Accordingly, Humana&#146;s reserves may be insufficient.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If Humana fails to effectively implement its operational and strategic initiatives, including its Medicare
initiatives, which are of particular importance given the concentration of the company&#146;s revenues in these products, state-based contract strategy, the growth of its CenterWell business, and its integrated care delivery model, the
company&#146;s business may be materially adversely affected. In addition, there can be no assurances that the company will be successful in maintaining or improving its Star ratings in future years. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If Humana fails to properly maintain the integrity of its data, to strategically maintain existing or implement
new information systems, to protect Humana&#146;s proprietary rights to its systems, or to defend against cyber-security attacks or prevent other privacy or data security incidents that result in security breaches that disrupt the company&#146;s
operations or in the unintentional dissemination of sensitive personal information or proprietary or confidential information, the company&#146;s business may be materially adversely affected. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Humana is involved in various legal actions, or disputes that could lead to legal actions (such as, among other
things, provider contract disputes and qui tam litigation brought by individuals on behalf of the government), governmental and internal investigations, and routine internal review of business processes any of which, if resolved unfavorably to the
company, could result in substantial monetary damages or changes in its business practices. Increased litigation and negative publicity could also increase the company&#146;s cost of doing business. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As a government contractor, Humana is exposed to risks that may materially adversely affect its business or its
willingness or ability to participate in government healthcare programs including, among other things, loss of material government contracts; governmental audits and investigations; potential inadequacy of government determined payment rates;
potential restrictions on profitability, including by comparison of profitability of the company&#146;s Medicare Advantage business to <FONT STYLE="white-space:nowrap">non-Medicare</FONT> Advantage business; or other changes in the governmental
programs in which Humana participates. Changes to the risk-adjustment model utilized by CMS to adjust premiums paid to Medicare Advantage plans or retrospective recovery by CMS of previously paid premiums as a result of the final rule related to the
risk adjustment data validation audit methodology published by CMS on January&nbsp;30, 2023 (Final RADV Rule), which Humana believes fails to address adequately the statutory requirement of actuarial equivalence due to its failure to include a
&#147;Fee For Service Adjuster (FFS Adjuster)&#148;, could have a material adverse effect on the company&#146;s operating results, financial position and cash flows. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Humana&#146;s business activities are subject to substantial government regulation. New laws or regulations, or
legislative, judicial, or regulatory changes in existing laws or regulations or their manner of application could increase the company&#146;s cost of doing business and have a material adverse effect on Humana&#146;s results of operations (including
restricting revenue, enrollment and premium growth in certain products and market segments, restricting the company&#146;s ability to expand into new markets, increasing the company&#146;s medical and operating costs by, among other things,
requiring a minimum benefit ratio on insured products, lowering the company&#146;s Medicare payment rates and increasing the company&#146;s expenses associated with a <FONT STYLE="white-space:nowrap">non-deductible</FONT> health insurance industry
fee and other assessments); the company&#146;s financial position (including the company&#146;s ability to maintain the value of its goodwill); and the company&#146;s cash flows. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Humana&#146;s failure to manage acquisitions, divestitures and other significant transactions successfully may
have a material adverse effect on the company&#146;s results of operations, financial position, and cash flows. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If Humana fails to develop and maintain satisfactory relationships with the providers of care to its members, the
company&#146;s business may be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Humana faces significant competition in attracting and retaining talented employees. Further, managing succession
for, and retention of, key executives is critical to the company&#146;s success, and its failure to do so could adversely affect the company&#146;s businesses, operating results and/or future performance. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Humana&#146;s pharmacy business is highly competitive and subjects it to regulations and supply chain risks in
addition to those the company faces with its core health benefits businesses. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Changes in the prescription drug industry pricing benchmarks may adversely affect Humana&#146;s financial
performance. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Humana&#146;s ability to obtain funds from certain of its licensed subsidiaries is restricted by state insurance
regulations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Downgrades in Humana&#146;s debt ratings, should they occur, may adversely affect its business, results of
operations, and financial condition. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The securities and credit markets may experience volatility and disruption, which may adversely affect
Humana&#146;s business. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The spread of, and response to, the novel coronavirus, or <FONT STYLE="white-space:nowrap">COVID-19,</FONT>
underscores certain risks Humana faces, including those discussed above, and the ongoing, heightened uncertainty created by the pandemic precludes any prediction as to the ultimate adverse impact to Humana of
<FONT STYLE="white-space:nowrap">COVID-19.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic
continues, the premiums the company charges may prove to be insufficient to cover the cost of health care services delivered to its members, each of which could be impacted by many factors, including the impacts that Humana has experienced, and may
continue to experience, to its revenues due to limitations on its ability to implement clinical initiatives to manage health care costs and chronic conditions of its members, and appropriately document their risk profiles, as a result of the
company&#146;s members being unable or unwilling to see their providers due to actions taken to mitigate the spread of <FONT STYLE="white-space:nowrap">COVID-19;</FONT> increased costs that may result from higher utilization rates of medical
facilities and services and other increases in associated hospital and pharmaceutical costs; and shifts in the company&#146;s premium and medical claims cost trends to reflect the demographic impact of higher mortality during the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. In addition, Humana is offering, and has been mandated by legislative and regulatory action (including the Families First Act and CARES Act) to provide, certain expanded benefit coverage to its
members, such as waiving, or reimbursing, certain costs for <FONT STYLE="white-space:nowrap">COVID-19</FONT> testing, vaccinations and treatment. These measures taken by Humana, or governmental action, to respond to the ongoing impact of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(including further expansion or modification of the services delivered to its members, the
adoption or modification of regulatory requirements associated with those services and the costs and challenges associated with ensuring timely compliance with such requirements), and the potential for widespread testing, treatments and the
distribution and administration of <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccines, could adversely impact the company&#146;s profitability. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The spread and impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> and additional variants, or actions taken to mitigate this spread,
could have material and adverse effects on Humana&#146;s ability to operate effectively, including as a result of the complete or partial closure of facilities or labor shortages. Disruptions in public and private infrastructure, including
communications, availability of <FONT STYLE="white-space:nowrap">in-person</FONT> sales and marketing channels, financial services and supply chains, could materially and adversely disrupt the company&#146;s normal business operations. A significant
subset of the company&#146;s and the company&#146;s third party providers&#146; employee population are in a remote work environment in an effort to mitigate the spread of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> which may exacerbate
certain risks to Humana&#146;s business, including an increased demand for information technology resources, increased risk of phishing and other cybersecurity attacks, and increased risk of unauthorized dissemination of sensitive personal,
proprietary, or confidential information. The continued <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has severely impacted global economic activity, including the businesses of some of Humana&#146;s commercial customers, and caused
significant volatility and negative pressure in the financial markets. In addition to disrupting Humana&#146;s operations, these developments may adversely affect the timing of commercial customer premium collections and corresponding claim
payments, the value of the company&#146;s investment portfolio, or future liquidity needs. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The ongoing, heightened uncertainty created by
the pandemic precludes any prediction as to the ultimate adverse impact to Humana of <FONT STYLE="white-space:nowrap">COVID-19.</FONT> Humana is continuing to monitor the spread of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> changes to the
company&#146;s benefit coverages, and the ongoing costs and business impacts of dealing with <FONT STYLE="white-space:nowrap">COVID-19,</FONT> including the potential costs and impacts associated with lifting or reimposing restrictions on movement
and economic activity, the timing and degree in resumption of demand for deferred healthcare services, the pace of administration of <FONT STYLE="white-space:nowrap">COVID-19</FONT> vaccines and the effectiveness of those vaccines, and related
risks. The magnitude and duration of the pandemic remain uncertain, and its impact on Humana&#146;s business, results of operations, financial position, and cash flows could be material. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In making forward-looking statements, Humana is not undertaking to address or update them in future filings or communications regarding its business or
results. In light of these risks, uncertainties, and assumptions, the forward-looking events discussed herein may or may not occur. There also may be other risks that the company is unable to predict at this time. Any of these risks and
uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Humana advises investors to
read the following documents as filed by the company with the SEC for further discussion both of the risks it faces and its historical performance: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Form <FONT STYLE="white-space:nowrap">8-Ks</FONT> filed during 2023. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>About Humana </U></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Humana Inc. (NYSE: HUM) is committed
to helping our millions of medical and specialty members achieve their best health. Our successful history in care delivery and health plan administration is helping us create a new kind of integrated care with the power to improve health and
well-being and lower costs. Our efforts are leading to a better quality of life for people with Medicare, families, individuals, military service personnel, and communities at large. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To accomplish that, we support physicians and other health care professionals as they work to deliver the right care in the right place for their patients,
our members. Our range of clinical capabilities, resources and tools &#150; such as <FONT STYLE="white-space:nowrap">in-home</FONT> care, behavioral health, pharmacy services, data analytics and wellness solutions &#150; combine to produce a
simplified experience that makes health care easier to navigate and more effective. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>hum-20230227.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 3/1/2023 1:39:54 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:hum="http://www.humana.com/20230227"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.humana.com/20230227"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hum-20230227_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hum-20230227_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>hum-20230227_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 3/1/2023 1:39:54 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>hum-20230227_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 3/1/2023 1:39:54 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="hum-20230227.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g461254g0228134644724.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g461254g0228134644724.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  L -(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#T;QCXAU+2
M]6CM[2540P[SE0><GUK=\*:C<:IH4=Q=,&E+,I(&,X-<=\0?^0]%_P!<!_,U
MTW@,_P#%-1_]=&_G7F4JDWBY1;T_X8YX2?M6CIZ\TUSQ9K%IK5W;P7"K'$^%
M&P'BO2Z\:\2_\C'J _Z:5>8U)P@G!VU'7DXQT/6M+F>YTJUFEY>2)68^Y%6Z
MPXKXZ=X/ANU3S&BME8*3C/%9>@^,WUC58[-K,1;U)W;\]*Z/K$(N,)/5FO,E
M9,["BD8[5)]!7#6WC^6XU&*U^PJJR2B/=YG3)Q55:\*32D]PE-1W.ZHK*U[6
MH]#L5N)(FDW-L55..<9_I7'3_$6\)_<642#_ &VW']*BKBJ5)\LGJ3.I&&YZ
M-17GEK\1K@/BZLD=<X)B;!_(U+>_$4AF6RLQ@='E;K^ K/Z_0M>XO;T[7N=]
M17GEI\1;@.OVNSC9">3$V"/P-=S87]OJ5HEU;2!XG'!';V-;4<13J_ RH5(S
MV+5%8>O^)K704575I;AQE(E]/4GL*Y*3XC7Q<^7:0(O8%BQ_/BIJXRC2ERR>
MHI581=FSTFBO/(OB1,%_?:>K>Z/BNTBU..31EU(JPC,/G%>^,9Q3I8FE5OR/
M8<:D9;%^BN F^(['/V?3N.S22?TJF/B)J6[)M[8K[9_QK)YA03M<GV]/N>ET
M5R^@>,[;5YQ;31FWN&^X"<J_T/K[5TTDB11L[L%51DD]JZ:=6%2/-%Z%QDI*
MZ'45PVI?$)(YFCL+;S5' E<X!^E9\?Q%OPWSVUNX] 2/ZUS2Q]"+M<AUX)VN
M>DT5RF@>,UUJ_6S:S:%V4L&#[AQ75UTTZL*BYH.Y<9*2N@HHHK0H\R^(7_(?
MA_Z]Q_,UB6&N:GIL+16-RT<;')^7<,_B#6W\0?\ D/1?]>X_F:Z3P+%&WAM"
MR*3YC<D5X3I2J8N2B[''RN55I.QQ9\7>(!Q]O;_OTO\ A6/<W,UY/)<3OODD
M^9FP!D_A7N!MX2,>4F#_ +(KQK788[?6[Z*-0L:RG:H[5.,P]2G%.4[H56$H
MI-NYZ+>_\D_/_7FO\A7&^!_^1GM_^N;?RKLKW_DG_P#VYK_(5QO@C_D:(,_\
M\V_E6]?^/2^1=3^)$]5D_P!6WT->+:?_ ,AZT_Z^E_\ 0J]ID_U;?0UXMI__
M "'[3_KZ7_T*KS/XJ?J/$;Q.\^(?_("A_P"NX_D:Q/ FG6E_<7INK>.7RU3;
MO&<9SFMOXA?\@.'_ *[C^1K/^''^MU#Z)_6IFD\<D^PI*]=$/CC0[*PBM[NU
MA6+>^QU3@'C(./PJ/P+I=EJ,EY)=VZ2M%M"A^0,Y[=*U_B+_ ,@BV_Z[_P!#
M53X<==1^J?UJ?9P^O<MM/^ '*O;%/QUI%GI\EM<6L*Q^;E75>AQC!Q6A\.9G
M,%]"3^[1E91Z$CG^5'Q'_P!18?[[?RJ/X<?\Q'ZI_6G&*CCK1_K0+6KZ'+:]
M<27_ (ANW<DYF\M!GH <"O2=.\+:5:V4<;VD4K[1O=UR6->87G&N7&>,71_]
M"KVF/_5K]!3P$8SG.4E=W'12;;9Y-XOM;>R\0216T2Q1B,':HXR:[JW_ .1!
M'_7B?_0:XSQS_P C--_US7^5=I;_ /(A+_UY?^RTL,DJ]5+S%3^.1YUX=MH[
MO7K.WG0/$S893T/!KT^;PSH\L+1?8(5!&,JN"/QKS7PG_P C+8?[Y_D:]AJL
MNIPE3?,KZAADG%W/$GW:7K3")LFVN,+GOAJ]#\<7K0>'%"<&X=4/TQG^E>>Z
MQ_R'K[_KY;_T*NW\?C_BG[+_ *[+_P"@FL*#<:55(F#:C.Q@^"]$M]5OIGND
MWQ0*/D[,3TS75>)=$TVW\/7<T5C DB)E65 "*R_APWS7X[_(?YUT?BS_ )%B
M^_ZY_P!:Z<+3A]5<K:ZFE.*]E<X+P/SXG@_ZYM7J]>4>!O\ D9H/^N;?RKU>
MKRS^#\QX;X HHHKT3<\R^(/_ "'XN?\ EW'\S73> S_Q3,?_ %T;^=:FHZ%I
MVI3K-=VXDD4;02>U6K*RM]/ME@M8A'&.BBN"E0<<3*I?<QC3M4<BS7C/B;_D
M8K__ *ZU[-6-<^&])O+E[B>S5I9#EFR>:K'476@HIA6@YJR$M[3^T/",5KG;
MYUJ%SZ96O+K6YNM U@2A MQ Q4H_1NQ%>S0Q)! D4:[40!5'H*J7^C:=J7-W
M:1R,.C$<_G4XC#.HHRB[-"J4G))IZHX]_B.S1%1IGS$8YFX_E7):8V_6[+GE
MKE#^M>EIX-T+=G[%GZNW^-:-MHNF695H+&!'7HVP9'XUS_5JU>2<Y+0GV<YV
M<F8/Q#_Y 4/_ %W'\C6?\-R/-U#'HG]:[/4=.M=3A6&[B$D8.X GO4>G:18Z
M69#9P+%YF-V#UQTKHEAV\4JE]O\ (MP?M.8YSXB_\@BV_P"N_P#0U5^&_P#S
M$/JG]:['4=-M-3A6*\A65%;< ?6F:=I-CI@D^QP"+S,;L'KBCV#^M>TN/D_>
M<QROQ'_U-A_OM_*H_AO_ ,Q'ZI_6NOU+2K+4XT2\@654.5SVI--TBRTOS/L<
M B\S&[!ZXH]@_K7M+BY/WG,>:^+M*DT_6YYBA\BX8NC#ID]1]<UJ6/Q!E@LD
MCN;+S)$4+O5\;L=S7?75K!=PF*XA25#U5QD5CQ>$]$CG\T6*%@<@,21^592P
MU2G5;I2LF2Z<HRO%GFFLZE<:I?M>748C:1/E4 XV]OK]:])M_P#D0E_Z\?\
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J1E2I<J?4NG!QC89;ZDD]M%-L8>8@;&/49HJZ(T4 !0 .!Q17;:7<V/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139885440195088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 27, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HUMANA INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000049071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 27,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-05975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">61-0647538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 W. Main Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Louisville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">KY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">40202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(502)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">580-1000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HUM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>d461254d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="hum-20230227.xsd" xlink:type="simple"/>
    <context id="duration_2023-02-27_to_2023-02-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
        </entity>
        <period>
            <startDate>2023-02-27</startDate>
            <endDate>2023-02-27</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2023-02-27_to_2023-02-27"
      id="Hidden_dei_EntityRegistrantName">HUMANA INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2023-02-27_to_2023-02-27">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-02-27_to_2023-02-27"
      id="Hidden_dei_EntityCentralIndexKey">0000049071</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-02-27_to_2023-02-27">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-02-27_to_2023-02-27">2023-02-27</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-02-27_to_2023-02-27">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-02-27_to_2023-02-27">001-05975</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-02-27_to_2023-02-27">61-0647538</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-02-27_to_2023-02-27">500 W. Main Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-02-27_to_2023-02-27">Louisville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-02-27_to_2023-02-27">KY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-02-27_to_2023-02-27">40202</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-02-27_to_2023-02-27">(502)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-02-27_to_2023-02-27">580-1000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-02-27_to_2023-02-27">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-02-27_to_2023-02-27">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-02-27_to_2023-02-27">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-02-27_to_2023-02-27">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-02-27_to_2023-02-27">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-02-27_to_2023-02-27">HUM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-02-27_to_2023-02-27">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-02-27_to_2023-02-27">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M\&15G&J+AI%I?I)<20/GTOQRRRB,<]L!OE]+:3X:]G!:_K8P^@]02P,$%
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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M2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @ AI%<5B0>FZ*M    ^ $  !H
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M_0QI-^2!8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%
M  @ AI%<5@=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " "&D5Q6>CF'Y^T    K @  $0
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M<R\N<F5L<U!+ 0(4 Q0    ( (:17%8<.&7J/P$  #P"   /
M  "  3D0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "&D5Q6)!Z;HJT
M  #X 0  &@              @ &E$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " "&D5Q699!YDAD!  #/ P  $P
M@ &*$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #4$P
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d461254d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName -  d461254d8k.htm 7</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="d461254d8k.htm">d461254d8k.htm</File>
    <File>d461254dex11.htm</File>
    <File>d461254dex991.htm</File>
    <File>hum-20230227.xsd</File>
    <File>hum-20230227_lab.xml</File>
    <File>hum-20230227_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d461254d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d461254d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "hum-20230227_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hum-20230227_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "hum-20230227.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "hum",
   "nsuri": "http://www.humana.com/20230227",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d461254d8k.htm",
      "contextRef": "duration_2023-02-27_to_2023-02-27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d461254d8k.htm",
      "contextRef": "duration_2023-02-27_to_2023-02-27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.humana.com//20230227/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-23-054410-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-054410-xbrl.zip
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M+.BT0LX5,BY L2R-:L-0YJBNP\X4+JBCXLOUDK<&,3.:&]Z'PA/[0VJ[2"9
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M86($EAF"@8'=XV&DSDL.V80ZHTA7*:,3=L!41X"E@&HZ(-:$"]B8M2GY\="
MZ30L&7Z]J*F9#9HTQZZ-FU98/XIZ'A)(;;PRVC92@536&7TA_9TP)HVMR8KE
MK]55MKQ'>!=+AWRTR=2I]N_)UFW%SX=_=O;WFNKGNI^[I>3_:;JW<%:55?(/
M/G'+MS1P\*6C'YGCZ[?!OB;Y-EP*WPMAMO)&+DZ>]UW<WP5:7L[NX^L5U-'"
M_V%%++KRZN<((1"<V&P$]C2^/W2CWEDJ5 "'OS<JN.,\[87%CX&V>!L7YF9A
M.UA-5D2^Z<9W'ZYS8![DL.!O^UB=-<699(U?>UK5O\*J?J/U[+]02P,$%
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MD,=^$R&]"AV;N429B]_RCI>+G!5S?+M5;W75'89-_R!)P,W&:%*:E7,1"PI
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M")&C')M9D_=]I$=O=19G2)Z"M!:J8A J\BL*%<"/P"IPL4B'DQ;*T:8F"SP
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M[D W92,E#+::1A3+!$>/%60"E6I3KC<WR\63C+%"\<N4;<N&!+X&AB2]H<H
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M]!?TODS&JM8WR#E[2A'/J7WOK8H*+OMB.V#*Z$ @1G()_6/]1.]!Q!>[I?E
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MMKI?E08S$-N56XGOI)&8I8 X0:H/7QJ?Q=[Q:^R=^:E3#I>Y3@&K)K)_5?$
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M7!!?N:P"D"0B@HO ]))ZP3CH*0<&_]>6(*;NBW=,]53FN?JT="!)_F'MMX?
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M'% PJ4DT>  6?B=(_T7"!?JK)BQO/T3UF^,CKN41QNJM'R@@0:&=.0:* V-
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MH#\+>]+K!LD7_ 3VZL$#H\FHLB6PO>) [+I!V*<&4'BCYD7QI.2=9"]8L>#
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MCIC@S^R:GAG&N8>"DV?$(&])7>.JWP?7XEP<[M=&2+N.<O=-/S %;VI%>MD
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M1PDS+IN$[Z!IH3,34A/.->6^FD_'S2U.1B0S1K1 / _*'7@W4NK?PG7_C<D
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MOK?D%DJ+PYI%#Z@!I/V(M\D^2L\]/&]N/*^SOD%7UV;^-?7+I6[ O\@@RB;
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MQ.NGO0GW6]"V*_2L4&>$&P4RP!(*;/A S%A>?=!-)]RS(4_!MQ#5%#'7O3^
M*LAFER%],@^M!>#3!]@)0PTH.<.]'K]^>W"&S2UJ#;^'70_^%B(/7E]?KP,/
MKU^F5^O>@>DIP;89LPZ?>'6"3477P.VP,%2FV"L3!C'"+5-_#H8V^ ;QNS0#
M4'^+=*9PUP]L"T^W=**\V[L\M6A [\5.'32JHP(IA687/J,6FP>>',=K1-1
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M8?KE:%H1"6]M'BQE?-22Y&,_<(;MW6\8-O">,WB8[O8_E3J!1_]C:["])]Z
M'0AT+D[5L!*7HY$J=3X.006 =!& +5W^YTGDS9PI^K>_;.UMO<2]WZIA6<MR
MQ@C>?MX38*/N\/<1#8LGU40)^'CW^4O ="'S&?YQ\/*I>/+Q]^NS0_'^EP]/
MA<QS4^>)2D5E4CD3U4160E=B(JTH$!FID**HAYE.A'$HZ';,B%'$, P=GL!)
MD^-QJ<8H*N#E/-&%S(2<P@X5O"VLRC68#+FIE!V(FXFRJO69D*42"&RI+6R,
MNX /R)M,W2;P(1XL.M+^2ROV!L_]@Z!:\%Y;"_=$6BO$TWY/2 H.O3C8;3_N
MUKT'MLS3;N<_GN^M",;>*F#L[3 8^X/=G:W5P'B2&*"$I-*W*IOU1'.WU[S^
M1\*?)U+KKIJ0+!8_0LA67PI8E&Y?))F!^S!YMP,J)YDP7%L[3%\]8>OA'_ L
M/HF[6] !=B23RF$CJ<$<!+*?T3K(*(G)4TV*8B >%DK?AE]NFKMP9[(B5Q7@
MT21*I5:,2C,EN!] QAW<:[<S5$(6\,X7/04:SF9$Y5M;;3*7(Q :(E5I#8>'
M<];@;Y9W)4C"TC(AB%3;!*_-(OD(,)1IO31P$,&86\<% 7(-XB@'8 '%-5P%
M@ONH0\![I2J BTU=@94%Z(>MF( L@PFL;>\S5;=S"E;\#  \+>6=N%'E5%P8
MF0\ Q8_8'OA??0'Q:3T5.]HMU3]J73*1W8=O:,K2W-$"#8B+X4&FP74!G6H9
M(%Z,9 J1CE<KX&9KE"DC>'RLP+>4<-U),&R*&OYED4-!I243H$>\C22K4]Z(
MP)XZ!ET(,>PW!1[6P+*%!&Y&M(U+.1V(8\+'J4K4=*A*1OS.%K'5-G-R"QTR
MDR"/W<H+9,P#J+F3"RZ6R _70,HJ,92&I^UV\*8 6\#-\ R)_$4@X)(7YV\N
MKT21U5: CPM?60V*P<!Z/X"KWX <@L-:<2(+70%F4;'UQ E(E7%IZD*\RPP
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M3+A*]>94%ZU>R2&(B K\9V\0XG( 4X;7E0+Z+ (G*>Z@TH&_GV9C?PO6@^G
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M]5T8DNO;_@,)R<R8N6Y'T6*Q:*03)K3DN<&0NI'(+")AZ.KW1E_(K^OFVF0
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M,+D^8M_LXW]8\A=02P$"% ,4    " "&D5Q6DI?U4%X4   %>0  #@
M        @ $     9#0V,3(U-&0X:RYH=&U02P$"% ,4    " "&D5Q66S(.
M W]R  "HO0( $               @ &*%   9#0V,3(U-&1E>#$Q+FAT;5!+
M 0(4 Q0    ( (:17%8IAA=8;AT  "6%   1              "  3>'  !D
M-#8Q,C4T9&5X.3DQ+FAT;5!+ 0(4 Q0    ( (:17%;A2)Y".0,  $(+   0
M              "  =2D  !H=6TM,C R,S R,C<N>'-D4$L! A0#%     @
MAI%<5B\H@1%?!@  O4,  !0              ( !.Z@  &AU;2TR,#(S,#(R
M-U]L86(N>&UL4$L! A0#%     @ AI%<5C3B"]RS!   =BH  !0
M     ( !S*X  &AU;2TR,#(S,#(R-U]P<F4N>&UL4$L%!@     &  8 >P$
' +&S      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
